CareDx (CDNA) 10-Q 9 Jun 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Jun. 05, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	CDNA
Entity Registrant Name	CareDx, Inc.
Entity Central Index Key	1,217,234
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,421,016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 12,187	$ 17,258
Accounts receivable	3,378	2,768
Inventory	6,048	5,461
Prepaid and other assets	1,463	1,186
Total current assets	23,076	26,673
Property and equipment, net	2,768	2,931
Intangible assets, net	32,920	33,124
Goodwill	12,005	13,839
Restricted cash	9,553	143
Other assets	0	20
Total assets	80,322	76,730
Current liabilities:
Accounts payable	3,475	3,065
Accrued payroll liabilities	3,000	3,851
Accrued and other liabilities	5,843	5,320
Accrued royalties	287	263
Deferred revenue	39	42
Deferred purchase consideration	6,463	5,445
Derivative liability	1,510	0
Current debt	32,386	22,846
Total current liabilities	53,003	40,832
Deferred rent, net of current portion	1,205	1,301
Deferred revenue, net of current portion	760	759
Deferred tax liability	5,934	6,057
Long-term debt, net of current portion	0	1,098
Contingent consideration	271	492
Common stock warrant liability	2,759	5,208
Other liabilities	1,530	1,222
Total liabilities	65,462	56,969
Commitments and contingencies (Note 9)	0	0
Stockholders’ equity:
Preferred stock: $0.001 par value; 10,000,000 shares authorized at March 31, 2017 and December 31, 2016; no shares issued and outstanding at March 31, 2017 and December 31, 2016	0	0
Common stock: $0.001 par value; 100,000,000 shares authorized at March 31, 2017 and December 31, 2016; 21,358,292 shares and 21,278,373 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	21	21
Additional paid-in capital	236,122	235,673
Accumulated other comprehensive loss	(3,395)	(3,659)
Accumulated deficit	(218,115)	(212,553)
Total CareDx, Inc. stockholders' equity	14,633	19,482
Noncontrolling interest	227	279
Total stockholders’ equity	14,860	19,761
Total liabilities and stockholders’ equity	$ 80,322	$ 76,730

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	21,358,292	21,278,373
Common stock, shares outstanding	21,358,292	21,278,373

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Testing revenue	$ 7,902	$ 6,452
Product revenue	3,667	0
Collaboration, license and other revenue	15	110
Total revenue	11,584	6,562
Operating expenses:
Cost of testing	3,057	2,772
Cost of product	2,327	0
Research and development	3,283	3,159
Sales and marketing	3,222	1,737
General and administrative	6,502	5,676
Goodwill impairment	1,958	0
Change in estimated fair value of contingent consideration	(221)	(213)
Total operating expenses	20,128	13,131
Loss from operations	(8,544)	(6,569)
Interest expense	(790)	(266)
Other expense, net	(686)	(2,917)
Change in estimated fair value of common stock warrant liability and derivative liability	4,128	0
Loss before income taxes	(5,892)	(9,752)
Income tax benefit	283	0
Net loss	(5,609)	(9,752)
Net loss attributable to noncontrolling interest	(47)	0
Net loss attributable to CareDx, Inc.	$ (5,562)	$ (9,752)
Net loss per share attributable to CareDx, Inc. (Note 3):
Basic	$ (0.26)	$ (0.81)
Diluted	$ (0.26)	$ (0.81)
Weighted average shares used to compute net loss per share attributable to CareDx, Inc.:
Basic	21,343,782	11,969,714
Diluted	21,343,782	11,969,714

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,609)	$ (9,752)
Other comprehensive loss:
Foreign currency translation adjustments	264	0
Net Comprehensive loss	(5,345)	(9,752)
Comprehensive loss attributable to noncontrolling interest	(52)	0
Comprehensive loss attributable to CareDx, Inc.	$ (5,293)	$ (9,752)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (5,609)	$ (9,752)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	934	261
Amortization of inventory fair market value adjustment	32	0
Stock-based compensation	391	446
Amortization of deferred revenue	(2)	(16)
Amortization of debt discount and noncash interest expense	627	41
Revaluation of contingent consideration to estimated fair value	(221)	(213)
Revaluation of common stock warrant liability and derivative liability to estimated fair value	(4,128)	0
Non-cash goodwill impairment	1,958	0
Changes in operating assets and liabilities:
Accounts receivable	(576)	(145)
Inventory	470	171
Prepaid and other assets	(245)	563
Accounts payable	382	820
Accrued payroll liabilities	(865)	(758)
Accrued royalties	24	(10)
Accrued and other liabilities	358	2,400
Change in deferred taxes	(271)	0
Net cash used in operating activities	(6,741)	(6,192)
Investing activities:
Purchase of property and equipment	(68)	(109)
Restricted cash collateral on lease	(36)	0
Net cash used in investing activities	(104)	(109)
Financing activities:
Proceeds from debt, net of issuance costs	24,002
Restricted cash collateral on debt	(9,375)	0
Proceeds from issuance of common stock under employee stock purchase plan	44	175
Principal payments on debt and capital lease obligations	(12,915)	(16)
Proceeds from exercise of stock options		6
Net cash provided by financing activities	1,756	165
Effect of exchange rate changes on cash and cash equivalents	18	0
Net decrease in cash and cash equivalents	(5,071)	(6,136)
Cash and cash equivalents at beginning of period	17,258	29,888
Cash and cash equivalents at end of period	12,187	$ 23,752
Supplemental disclosure of cash flow information:
Deferred purchase consideration	$ 1,018

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. ORGANIZATION AND DESCRIPTION OF BUSINESS CareDx, Inc. (“CareDx” or the “Company”) together with its subsidiaries, is a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. The Company focuses on discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. In post-transplant diagnostics, the Company offers AlloMap®, which is a heart transplant molecular test (“AlloMap”). In pre-transplant diagnostics, the Company offers high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. AlloMap is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate to severe acute cellular rejection. Since 2008, the Company has sought to expand the adoption and utilization of its AlloMap solution through ongoing studies to substantiate the clinical utility and actionability of AlloMap, secure positive reimbursement decisions for AlloMap from large private and public payers, develop and enhance its relationships with key members of the transplant community, including opinion leaders at major transplant centers, and explore opportunities and technologies for the development of additional solutions for post-transplant surveillance. The Company believes the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, the Company believes AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. AlloMap has received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) for marketing and sale as a test to aid in the identification of recipients with a low probability of moderate or severe acute cellular rejection. A 510(k) submission is a premarketing submission made to the FDA. Clearance may be granted by the FDA if it finds the device or test provides satisfactory evidence pertaining to the claimed intended uses and indications for the device or test. The Company is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure®, its proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA (“dd-cfDNA”) after transplantation. Through the acquisition of ImmuMetrix, Inc. (“IMX”), a privately held development-stage company working on dd-cfDNA-based solutions in transplantation and other fields, the Company added to its existing know-how, expertise, and intellectual property the ability to apply dd-cfDNA technology to the surveillance of transplant recipients, which has contributed to the development of AlloSure. With the acquisition of CareDx, International AB, formerly Allenex AB (“Allenex” or “Olerup”), on April 14, 2016, the Company develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP is used to type HLA alleles based on the sequence specific primer (“SSP”) technology and has a market in Europe and selected other markets for pre-transplant solutions. The Company also offers XM-ONE®, a standardized test that identifies a patient’s antigens against HLA Class I or Class II, as well as antibodies against a donor’s endothelium. This cross-match test has primarily been used prior to kidney transplants. With the acquisition of the business assets of Conexio Genomics Pty Ltd (“Conexio”) on January 20, 2017, the Company offers a complete product range for sequence-based typing (“SBT”) of HLA alleles. Olerup SBT Resolver is a test kit for sequence based HLA typing, while Assign SBT is the companion software for sequence analysis. In 2014, Olerup began active development of a new HLA typing product, Olerup QTYPE, that uses real-time polymerase chain reaction (“PCR”) methodology. Olerup QTYPE was commercially launched at the end of September 2016. The Company’s headquarters are in Brisbane, California; primary operations are in Brisbane and Stockholm, Sweden; and the Company operates in two reportable segments. Liquidity and Going Concern The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) effective December 31, 2016, which requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements. The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $218.1 million at March 31, 2017. As of March 31, 2017, the Company had cash and cash of debt outstanding under its debt obligations, net of debt discount. In March 2017, the Company received net proceeds of $24.0 million in connection with the issuance of a convertible debt obligation to JGB Collateral LLC and certain of its affiliates (“JGB”), of which $11.2 million was used to repay the Company’s outstanding debt obligations to East West Bank. In addition, the debt agreement requires the Company to maintain a minimum of $9.4 million of cash at a named financial institution. These funds are restricted as to withdrawal and are not available to the Company to fund its operations or repay indebtedness. Pursuant to the Company’s convertible debt financing agreements, the Company was required to file a registration statement with the SEC registering for resale the shares underlying the securities issued or issuable to JGB in the financing. Because the Company failed to file the registration statement with the SEC by April 17, 2017, commencing on April 18, 2017, the Company began accruing liquidated damages payable to JGB at a rate of approximately $7,000 per day. These damages accrued at the same rate on a daily basis until the registration statement was filed with the SEC on April 26, 2017. On May 3, 2017, JGB waived any claim or right to receive liquidated damages for the late filing of the registration statement. A quarterly debt covenant in the Company’s Term Loan Facility Agreement (the “Term Loan Facility”) with Danske Bank A/S (“Danske”) relating to maintaining an adequate leverage ratio was violated in June 30, 2016 and September 30, 2016. The Company obtained waivers from Danske for the violations of the debt covenant at June 30, 2016 and September 30, 2016. The debt covenant leverage ratio for December 31, 2016 and future periods was amended on March 27, 2017. The Company was in compliance with the amended debt covenants at December 31, 2016. The Company believes its cash and cash equivalents of $12.2 million at March 31, 2017 and expected revenues will not be sufficient to allow the Company to fund its current operations beyond June 30, 2017. The Company will require additional financing and/or refinancing of its current debt obligations to fund working capital, repay debt and pay its obligations. The Company may pursue financing and refinancing opportunities in both the private and public debt and equity markets through sales of debt or equity securities. Additional financing might include one or more offerings and one or more of a combination of discounted or at-the-market common stock, securities convertible into or exchangeable for shares of common stock, warrants or other rights to purchase or acquire common stock. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable to the Company. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of the issuance of these financial statements. If the Company is unsuccessful in its efforts to raise additional financing and/or refinance the Company’s indebtedness in the near term, the Company will be required to significantly reduce or cease operations. Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern, the entire amount of borrowings was classified as current at March 31, 2017. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed consolidated balance sheet as of December 31, 2016 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany transactions have been eliminated. Since the Company owns less than 100% of the shares of Allenex, the Company records net loss attributable to noncontrolling interest in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, including from acquisitions, (vi) inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii) any impairment of long-lived assets, including in-process technology and goodwill, and (xiii) legal contingencies. Actual results could differ from those estimates. Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits. The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers, and sales of Olerup products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., Latin America and other geographic regions. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds. Restricted Cash Under lease agreements for certain facilities and an agreement with the State of Florida Medicaid, the Company must maintain letters of credit, minimum collateral requirements and a surety bond. These agreements are collateralized by cash. The cash used to support these arrangements is classified as long-term restricted cash on the accompanying balance sheets. Under the Company’s convertible debt financing agreements with JGB, the Company is required to maintain restricted cash of $9.4 million, which is restricted as to withdrawal and is not available to the Company to fund its operations or repay indebtedness. The restricted cash used to support the convertible debt facility Inventory Inventory is finished goods, work in progress and raw materials and consist of AlloMap reagent plates, laboratory supplies, reagents, Olerup SBT kits and Olerup SSP kits. Inventories are used in connection with tests performed and may also be used for research and product development efforts. Laboratory supplies subsequently designated for research and product development use are expensed. Obsolete or damaged inventories are written off and excluded from the physical inventory. Inventories at our Stockholm, Sweden and Fremantle, Australia locations are stated at the lower of purchased cost, determined on an average cost basis, or net realizable value. Inventories at our other locations are stated at the lower of purchased cost, determined on a first-in, first-out basis or net realizable value. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, generally three years for laboratory, computer and office equipment, and generally seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of their estimated useful lives or the remaining lease term. Assets held under capital leases are recorded at the lower of the net present value of the minimum lease payments or the fair market value of the leased asset at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the assets or the period of the related lease. The Company capitalizes certain costs incurred for software developed or obtained for internal use. These costs include software licenses, consulting services, and direct materials, as well as employee payroll and payroll-related costs. Capitalized internal-use software costs are depreciated over three years. Purchased Intangible Assets Amortizable intangible assets include customer relationships, developed technology, trademarks, contracts and in-process research and development (“IPR&D”) identified intangible assets acquired as part of a business combination. Intangible assets subject to amortization are amortized over their estimated useful lives. Acquired intangible assets with indefinite useful lives are related to IPR&D projects and are measured at their respective fair values as of the acquisition date. The Company does not amortize intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests IPR&D for impairment on an annual basis and in between annual tests if it becomes aware of events or changes that would indicate that it is more likely than not that the fair value of the assets is below their carrying amounts. The IPR&D annual impairment test is performed as of December 1 of each fiscal year. If the fair value exceeds the carrying value, then there is no impairment. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of an asset to its carrying value, without consideration of any recoverability test. The Company has not identified any such impairment losses to date. Impairment of Long-lived Assets The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date. Goodwill Goodwill represents the excess of the cost of an acquisition over the sum of the amounts assigned to tangible and identifiable intangible assets acquired, less liabilities assumed. Goodwill is not subject to amortization, but is tested for impairment on an annual basis and whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. The Company has determined that it operates in two reportable segments associated with the delivery of diagnostic tests and the development and commercialization of diagnostic products. The reporting unit’s carrying value is compared to its fair value and an impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss should not exceed the total amount of goodwill allocated to the reporting unit. The estimated fair values of the reporting units are determined using either the market approach, income approach or a combination of the market and income approach. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its estimated fair value. The income approach uses expected future operating results and failure to achieve these expected results may cause a future impairment of goodwill at the reporting unit. The Company conducted a goodwill impairment test as of March 31, 2017 and identified an impairment of $2.0 million related to the goodwill recorded in the Olerup reportable segment. See Note 6 for additional discussion regarding the impairment charge recorded. Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability. The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the common stock warrant liability, derivative liability and contingent consideration liability also represents their fair values. Common Stock On April 14, 2016 and June 15, 2016, the Company completed the Private Placement and Subsequent Financing, respectively (as described in Note 12), which included the issuance of free standing warrants to certain accredited investors and placement agents to purchase shares of the Company’s common stock. The exercisability of the warrants was contingent upon the receipt of approval of the Private Placement by the Company’s stockholders pursuant to the rules of The NASDAQ Stock Market LLC (the “Requisite Stockholder Approval”), which occurred on June 16, 2016. The free standing warrants issued pursuant to the Private Placement and Subsequent Financing are contingently redeemable and are classified as liabilities on the consolidated balance sheet and recorded at their estimated fair value. The warrants are remeasured at each balance sheet date with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability on the consolidated statements of operations. On March 15, 2017, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued Senior Secured Debentures and warrants (as described in Note 11). The Company determined that the Debentures and the warrants were free standing instruments. The terms of the warrants include a price-based anti-dilution adjustment provision, which precludes the Company from classifying the warrants in equity. As such, the warrants are classified as liabilities on the consolidated balance sheet. The full fair value of the warrants was allocated on day one to the warrant liability and the residual value, after allocation of the fair value of the derivative liability discussed below, was ascribed to the Debentures. The warrants will be re-measured at each reporting period with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability on the consolidated statements of operations. The Debentures are classified as liabilities on the consolidated balance sheet and include certain embedded derivatives that required bifurcation, including settlement and penalty provisions. The compound embedded derivative will be re-measured at each reporting period with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability on the consolidated statements of operations. Testing Revenue The Company recognizes revenues for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. For testing revenue, the first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered. If all criteria set forth above are met, revenue is recognized on an accrual basis when the test is performed. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received. Revenue for tests performed is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date. Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations. Product Revenue Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when persuasive evidence of an arrangement exists, the product is complete and tested and has been shipped or delivered, as required to transfer title and risk of loss, the sales price is fixed and determinable, collection of the resulting receivable is reasonably assured, there are no material contingencies and the Company does not have significant obligations for future performance. When collectability is not reasonably assured, the Company defers the revenue until the cash is received. Provisions for estimated future product returns and allowances are recorded in the period of the sale based on the historical and anticipated future rate of returns. Revenue is recorded net of any discounts given to the buyer. Collaboration, License and Other Revenue The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the three months ended March 31, 2017 or 2016. Cost of Testing Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation, utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when the testing revenue is recognized with respect to that test. As a result, the Company’s cost of testing as a percentage of revenue may vary significantly from period to period because the Company does not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized. Cost of Product Cost of product reflects the aggregate costs incurred in delivering the Company’s products to customers. The components of cost of product are materials costs, manufacturing and kit assembly costs, direct labor costs, equipment and infrastructure expenses associated with preparing kitted products for shipment, shipping, and allocated overhead including rent, information technology, equipment depreciation and utilities. Cost of product also includes amortization of acquired developed technology and adjustments to inventory values, including write-down of impaired, slow moving or obsolete inventory. Business Combinations The Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition. Research and Development Expenses Research and development expenses represent costs incurred to develop new surveillance solutions as well as continued development of the Company’s AlloMap test. These expenses include payroll and related expenses, consulting expenses, laboratory supplies, and certain allocated expenses as well as amounts incurred under certain collaboration and license agreements. Research and development costs are expensed as incurred. The Company records accruals for estimated study costs comprised of work performed by contract research organizations under contract terms. Advertising Expenses All advertising costs are expensed as incurred. Advertising expenses were insignificant during all of the periods presented. Stock-based Compensation The Company uses the Black-Scholes Model, which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using its own historical stock prices and stock prices of peer companies in the diagnostics industry, risk-free rates using the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield using the Company’s expectations and historical data. The fair value of each restricted stock unit is calculated based upon the closing price of the Company’s common stock on the date of the grant. The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience. Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period. Income Taxes The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company’s assessment of an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available. Foreign Currency Translation The functional currency of the Company’s foreign subsidiaries is the local currency for each entity, including the Swedish Krona, Australian dollar and the Euro. The revenue and expenses of such subsidiaries have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the balance sheet date. The resulting cumulative translation adjustments are reported in other comprehensive loss. Foreign currency transaction gains and losses are recognized in current operations. Comprehensive (Loss) Income Comprehensive (loss) income consists of net (loss) income and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income or loss. For the Company, such items consist of foreign currency translation losses. Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”) In March 2016, the FASB issued ASU No 2016-09, Compensation - Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing . Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606), , In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force) . consolidated financial statements In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business . The Company adopted ASU No. 2017-01 on January 1, 2017 on a prospective basis and its adoption did not have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . .

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss Per Share	3. NET LOSS PER SHARE Basic and diluted net loss per share have been computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common share equivalents as their effect would have been antidilutive. The following tables set forth the computation of the Company’s basic and diluted net loss per share (in thousands, except shares and per share data): Three Months Ended March 31, 2017 2016 Numerator: Net loss attributable to CareDx, Inc. used to compute basic net loss per share $ (5,562 ) $ (9,752 ) Net loss attributable to CareDx, Inc. used to compute diluted net loss per share $ (5,562 ) $ (9,752 ) Denominator: Weighted-average shares used to compute basic net loss per share attributable to CareDx, Inc. 21,343,782 11,969,714 Weighted-average shares used to compute diluted net loss per share attributable to CareDx, Inc. 21,343,782 11,969,714 Net loss per share attributable to CareDx, Inc.: Basic $ (0.26 ) $ (0.81 ) Diluted $ (0.26 ) $ (0.81 ) The following potentially dilutive securities have been excluded from diluted net loss per share, because their effect would be antidilutive: Three Months Ended March 31, 2017 2016 Shares of common stock subject to outstanding options 1,881,416 1,860,420 Shares of common stock subject to outstanding common stock warrants 4,509,926 301,069 Shares of common stock subject to convertible notes 6,092,105 - Restricted stock units 440,910 178,975 Total common stock equivalents 12,924,357 2,340,464 The Company issued 4,630,145 shares of preferred stock pursuant to the Private Placement and Subsequent Financing, which were completed on April 14, 2016 and June 15, 2016, respectively. All of the preferred stock was converted to common stock upon receipt of the Requisite Stockholder Approval on June 16, 2016. As of March 31, 2017, there was no preferred stock outstanding. On September 26, 2016, the Company completed an underwritten public offering pursuant to which the Company issued and sold an aggregate of 2,250,000 shares of common stock.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. FAIR VALUE MEASUREMENTS The Company records its financial assets and liabilities at fair value except for its debt, which is recorded at amortized cost. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: • Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. • Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis, as of March 31, 2017 and December 31, 2016 (in thousands): March 31, 2017 Fair Value Measured Using (Level 1) (Level 2) (Level 3) Total Balance Assets Money market funds $ 11,723 $ — $ — $ 11,723 Liabilities Contingent consideration $ — $ — $ 271 $ 271 Common stock warrant liability — — 2,759 2,759 Derivative liability — — 1,510 1,510 Total liabilities $ — $ — $ 4,540 $ 4,540 December 31, 2016 Fair Value Measured Using (Level 1) (Level 2) (Level 3) Total Balance Assets Money market funds $ 14,497 $ — $ — $ 14,497 Liabilities Contingent consideration $ — $ — $ 492 $ 492 Common stock warrant liability — — 5,208 5,208 Total liabilities $ — $ — $ 5,700 $ 5,700 The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands): (Level 3) Contingent Consideration Liability Common Derivative Liability Total Balance as of December 31, 2016 $ 492 $ 5,208 $ — $ 5,700 Issuance of JGB debt and warrants — 900 2,290 3,190 Change in estimated fair value (221 ) (3,349 ) (780 ) (4,350 ) Balance as of March 31, 2017 $ 271 $ 2,759 $ 1,510 $ 4,540 The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between Level 1, Level 2 and Level 3 categories during the periods presented. In determining fair value, the Company uses various valuation approaches within the fair value measurement framework. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below: • Money market funds - Investments in money market funds are classified within Level 1. At March 31, 2017 and December 31, 2016, money market funds were included on the balance sheets in cash and cash equivalents. • Contingent consideration - As of March 31, 2017 and December 31, 2016, the Company had a contingent obligation to issue 227,845 shares of its common stock to the former owners of IMX in conjunction with its acquisition of IMX in June 2014. The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of dd-cfDNA in organ transplant recipients in the United States by June 10, 2020. The Company recorded its estimate of the fair value of the contingent consideration based on its evaluation of the probability of achievement of the contractual conditions that would result in the payment of the contingent consideration. The fair value of the contingent consideration was estimated using the fair value of the shares to be paid if the contingency is met multiplied by management’s estimate at March 31, 2017 and December 31, 2016 of the probability of success. The significant input in the Level 3 measurement not supported by market activity is the Company’s probability assessment of the milestone being met. The value of the liability is subsequently remeasured to fair value at each reporting date, and the change in estimated fair value is recorded to a component of operating expenses item captioned “change in estimated fair value of contingent consideration” until the milestone contingency is paid, expires or is no longer achievable. Increases (decreases) in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability. The carrying amount of the contingent consideration liability represents its fair value. The fair value of the contingent consideration decreased by $0.2 million in the three months ended March 31, 2017, as a result of the decreases in the fair market value of the Company’s common stock price during the period, partially offset by management’s estimate of the probability of meeting the milestone increasing to 85% at March 31, 2017 from 80% at December 31, 2016. • Common stock warrant liability – As of March 31, 2017, the Company had warrants to purchase 2,978,087 shares of common stock outstanding that it issued to certain accredited investors and its placement agents following the closing of the Private Placement on April 14, 2016 and Subsequent Financing on June 15, 2016. In addition, as of March 31, 2017, the Company had warrants to purchase 1,250,000 shares of common stock outstanding that it issued to JGB following the closing of the convertible debt agreement on March 15, 2017 (as described in Note 11). The common stock warrants are classified as liabilities within Level 3. The Company utilizes a binomial-lattice pricing model (the Monte Carlo simulation model) that involved a market condition to estimate the fair value of the warrants. The application of the Monte Carlo simulation model required the use of a number of complex assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and stock prices of peer companies in the diagnostics industry, and risk-free rates based on the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected life of the warrants. The estimated fair value of the warrants was subsequently remeasured at March 31, 2017, and the change in estimated fair value of common stock warrant liability was recorded on the Company’s condensed consolidated statements of operations. • Derivative liability – The JGB Debt (as described in Note 11) includes certain embedded derivatives that require bifurcation, including settlement and penalty provisions. The Company utilizes the Monte Carlo simulation model to estimate the fair value of the compound derivative liability for the measurement at issuance and subsequent remeasurement at March 31, 2017. The application of the Monte Carlo simulation model requires the use of a number of complex assumptions, which included the probability and size of additional financing rounds. Common Stock Warrant Liability and Derivative Liability Assumptions March 31, 2017 December 31, 2016 Private Placement Common Stock Warrant Liability Stock Price $ 1.40 $ 2.70 Exercise Price $ 4.00 $ 4.00 Remaining term (in years) 6.04 6.29 Volatility 54.00 % 51.40 % Risk-free interest rate 2.08 % 2.14 % Placement Agent Common Stock Warrant Liability Stock Price $ 1.40 $ 2.70 Exercise Price $ 3.99 $ 3.99 Remaining term (in years) 4.04 4.29 Volatility 60.30 % 56.10 % Risk-free interest rate 1.72 % 1.77 % March 31, 2017 March 15, 2017 JGB Common Stock Warrant Liability Stock Price $ 1.40 $ 2.15 Exercise Price $ 5.00 $ 5.00 Remaining term (in years) 5.46 5.50 Volatility 56.00 % 54.00 % Risk-free interest rate 1.98 % 2.06 % Derivative Liability Stock Price $ 1.40 $ 2.15 Remaining term (in years) 2.91 2.96 Volatility 56.00 % 54.00 % Risk-free interest rate 1.61 % 1.72 % The Company’s liabilities classified as Level 3 were valued based on unobservable inputs and management’s judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of the financial instruments. The Company has determined that debt at similar interest rates and terms to its current debt is not currently available to the Company and therefore the Company is unable to calculate the fair value of its debt at March 31, 2017.

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Business Combination	5. BUSINESS COMBINATION Allenex On April 14, 2016, the Company acquired 98.3% of the outstanding common stock of Allenex. Allenex is a transplant diagnostic company based in Stockholm, Sweden that develops, manufactures, and sells products that help match donor organs with potential recipients prior to transplantation. The acquisition of Allenex creates an international transplant diagnostics company with product offerings along the pre- and post-transplant continuum. The combined company has a presence and direct distribution channels in the United States and Europe, with additional third party distributors in Europe and other markets around the world. Under the terms of the Conditional Share Purchase Agreements entered into on December 16, 2015, as amended and the tender offer prospectus dated March 7, 2016, and as a result of the tender offer, the aggregate purchase consideration paid by the Company was approximately $34.1 million and consisted of (i) $26.9 million of cash, of which $5.7 million (which represents SEK 50,620,000 as of the acquisition date) was deferred purchase consideration originally payable to the Majority Shareholders by no later than March 31, 2017, subject to certain contingencies being met, and (ii) the issuance of 1,375,029 shares of the Company’s common stock valued at $7.2 million. The date by which the deferred purchase consideration was due to the Majority Shareholders was subsequently extended to July 1, 2017. In addition, interest began accruing on the Company’s obligations to the Majority Shareholders at a rate of 10.0% per year commencing on January 1, 2017 and will continue to accrue until the date the obligations are paid in full. Of the total cash consideration, $8.0 million of cash payable to the Majority Shareholders was deposited into an escrow account by the Company and subsequently invested in the Company by the Majority Shareholders through a purchase of the Company’s equity securities in the Subsequent Financing. Upon the completion of the Subsequent Financing, certain contingencies in the Conditional Share Purchase Agreements were waived. The Company determined at the date of the acquisition that these contingencies would be waived. The Company intends to complete compulsory acquisition proceedings under Swedish law to purchase the remaining shares of Allenex. On June 8, 2016, the Company delisted Allenex’s common stock from Nasdaq Stockholm. The cash portion of the acquisition purchase price was paid from the Company’s general working capital. The Company has accounted for this transaction as a business combination in exchange for total consideration of approximately $34.1 million. Under business combination accounting, the total purchase price was allocated to Allenex’s net tangible and identifiable intangible assets based on their estimated fair values as of April 14, 2016. The fair value of the remaining 1.7% of noncontrolling interest in Allenex was estimated to be approximately SEK 5,100,000, or approximately $0.6 million in U.S. dollars, as of April 14, 2016. The fair value of the noncontrolling interest was determined based on the number of outstanding shares comprising the noncontrolling interest and Allenex’s stock price of SEK 2.48 per share as of the acquisition date. The noncontrolling interest was presented as a component of stockholders’ equity on the Company’s condensed consolidated balance sheets. Total Noncontrolling interest at December 31, 2016 $ 279 Foreign currency effect $ (5 ) Loss attributable to noncontrolling interest (47 ) Noncontrolling interest at March 31, 2017 $ 227 Acquisition of assets of Conexio Genomics Pty. Ltd On January 20, 2017, the Company completed a transaction to acquire Conexio business assets that the Company needed in order to continue selling the SBT product line. The Company was the exclusive distributor of the Conexio SBT product line for all countries excluding Australia. The Company purchased rights to many of the assets, such as machinery, facilities leases, know-how and the opportunity to retain key Conexio employees to continue producing and selling the SBT line of products. The Company will pay, by July 1, 2017, $0.5 million for finished and unfinished goods purchased from Conexio. In addition, the Company will make quarterly payments to Conexio of 20% of the gross revenue from the sale of the SBT line of products using the purchased assets up to an aggregate total of $0.7 million. The Company also assumed all obligations under the lease of the Conexio facilities, and any liabilities for product warranty claims up to $35,000. The Company accounted for this transaction as a business combination. The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date. Given the timing of the close of the transaction in the first quarter of 2017, the inventory and intangible assets amounts are preliminary and subject to change as the Company finalizes its fair value assessments (in thousands): Total Inventory $ 1,040 Property, plant and equipment 97 Intangible assets 155 Goodwill 85 Assumed liabilities (82 ) Total preliminary acquisition consideration $ 1,295 The following table presents details of the identified intangible assets acquired at the acquisition date (in thousands): Estimated Fair Estimated Life (Years) Completed technology $ 127 9 Customer relationships 28 9 Total $ 155 Goodwill recorded from the acquisition of the Conexio business assets is primarily related to expected synergies. The goodwill resulting from the acquisition is not deductible for tax purposes. The post-acquisition results of operations of the Conexio business assets for the period from January 20, 2017 through March 31, 2017 are included in the Company’s consolidated statements of operations. Since the acquisition date, total revenue of the Conexio business assets for the period from January 20, 2017 through March 31, 2017 was $0.1 million. Net loss for the Conexio business assets for the period from January 20, 2017 through March 31, 2017 was $123,000. Unaudited Pro Forma Financial Information The unaudited pro forma financial information in the table below summarizes the combined results for the Company and Allenex as if the companies were combined as of January 1, 2016. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands). Three March 31, 2016 Revenue: Testing revenue $ 6,449 Product revenue 3,860 Other revenue 191 Total revenue $ 10,500 Net loss $ (6,313 ) The unaudited pro forma financial information for the three months ended March 31, 2016 was prepared using the acquisition method of accounting and has been adjusted to give effect to the pro forma events that are: (i) directly attributable to the acquisitions, (ii) factually supportable, and (iii) expected to have a continuing impact on the combined results. The pro forma adjustments directly attributable to the acquisition of Allenex exclude acquisition-related expenses of $2.3 million and debt financing costs of $2.9 million relating to a six-month bridge loan with Oberland Capital SA Davos LLC (“Oberland”) that did not materialize, together with the consequential tax effects.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. GOODWILL AND INTANGIBLE ASSETS Goodwill Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. The following table presents details of the Company’s goodwill by reporting unit as of March 31, 2017 (in thousands): CareDx Olerup Total Balance as of January 1, 2017 Goodwill $ 12,005 $ 14,855 $ 26,860 Accumulated impairment losses — $ (13,021 ) (13,021 ) 12,005 1,834 13,839 Goodwill acquired — 85 85 Impairment losses — (1,958 ) (1,958 ) Foreign currency translation adjustments — 39 39 Balance as of March 31, 2017 Goodwill 12,005 14,979 26,984 Accumulated impairment losses — (14,979 ) (14,979 ) $ 12,005 $ — $ 12,005 The gross carrying amount of goodwill may change due to the effects of foreign currency fluctuations as a result of acquiring an entity with a functional currency other than the U.S. dollar. Goodwill is tested annually for impairment at the reporting unit level during the fourth quarter and earlier upon the occurrence of certain events or substantive changes in circumstances. A reporting unit is either the "operating segment level" or one level below, which is referred to as a "component." The level at which the impairment test is performed requires judgment as to whether the operations below the operating segment constitute a self-sustaining business or whether the operations are similar such that they should be aggregated for purposes of the impairment test. The Company has concluded that it has two reporting units: CareDx (associated with the delivery of diagnostic tests) and Olerup (the development and commercialization of diagnostic products). On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The new standard simplifies how an entity is required to test goodwill for impairment and reduces the cost and complexity of evaluating goodwill for impairment. In the three months ended March 31, 2017, the Company determined that the decrease in its market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. The goodwill impairment test determined that the fair value of the Olerup reporting unit was $3.5 million, which was lower than its carrying value. Accordingly, the Company has recorded a goodwill impairment charge of $2.0 million as of March 31, 2017, which represented the remaining goodwill balance in the Olerup reporting unit. The significant assumptions utilized in the March 31, 2017 discounted cash flow analysis for the Olerup reporting unit was a discount rate of 16.6%, a terminal growth rate of 3.2% and a capitalization multiple of 7.48. The results of the quantitative test did not result in any impairments of Goodwill for the CareDx reporting unit, as the fair value of the reporting unit exceeded its respective carrying value by more than $20 million as of March 31, 2017. Intangible Assets The following tables present details of the Company’s intangible assets as of March 31, 2017 (in thousands): March 31, 2017 Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Amount Weighted Average Remaining Useful (In Intangible assets with finite lives: Customer relationships: Allenex $ 12,650 $ (772 ) $ (1,151 ) $ 10,727 13.8 Customer relationships: Conexio 28 (1 ) 1 28 8.8 Customer relationships 12,678 (773 ) (1,150 ) 10,755 Developed technology: SSP 11,650 (1,076 ) (1,051 ) 9,523 8.8 Acquired technology: QTYPE 4,510 (146 ) (415 ) 3,949 13.8 Acquired technology: SBT 127 (3 ) 2 126 8.8 Trademarks 2,260 (199 ) (144 ) 1,917 13.8 Total intangible assets with finite lives 31,225 (2,197 ) (2,758 ) 26,270 Acquired in-process technology ― 6,650 — — 6,650 — Total intangible assets $ 37,875 $ (2,197 ) $ (2,758 ) $ 32,920 The net carrying amount of intangible assets and the related amortization expense of intangible assets may change due to the effects of foreign currency fluctuations as a result of acquiring an entity with a functional currency other than the U.S. dollar. Amortization expense was $0.6 million for the three months ended March 31, 2017, of which $0.4 million and $0.2 million were amortized to cost of product and sales and marketing, respectively. There was no amortization recorded for the three months ended March 31, 2016, as the Company only had an intangible asset related to acquired in-process technology with an indefinite useful live in that period. Intangible assets are carried at cost less accumulated amortization. Amortization expenses are recorded to cost of product and sales and marketing. Acquired IPR&D of $6.7 million has not reached technological feasibility as of March 31, 2017 and is therefore not subject to amortization. As such, the Company excluded amortization of acquired in-process technology from the future amortization expense table below. The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of March 31, 2017 (in thousands): Years Ending December 31, Cost of Product Sales and Marketing Total Remainder of 2017 $ 1,042 $ 692 $ 1,734 2018 1,390 923 2,313 2019 1,390 923 2,313 2020 1,390 923 2,313 2021 1,390 923 2,313 2022 1,390 923 2,313 Thereafter 5,606 7,365 12,971 Total future amortization expense $ 13,598 $ 12,672 $ 26,270

Inventories

Inventories	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventories	7. INVENTORIES Inventory consisted of the following (in thousands): March 2017 December 2016 Finished goods $ 3,338 $ 4,199 Work in progress 1,745 159 Raw materials 965 1,103 Total inventory $ 6,048 $ 5,461

Accrued and Other Liabilities

Accrued and Other Liabilities	3 Months Ended
	Mar. 31, 2017
Payables And Accruals [Abstract]
Accrued and Other Liabilities	8. ACCRUED AND OTHER LIABILITIES Accrued and other liabilities consisted of the following (in thousands): March 2017 December 2016 Clinical studies $ 1,456 $ 1,375 Tax, audit and compliance related fees 1,323 275 Accrued interest payable on debt 866 862 Professional fees 299 345 Debt financing fees — 600 Test sample processing fees 578 524 Customer overpayments and refund reserve 225 281 Software implementation costs 130 176 Deferred rent – current portion 383 374 Capital leases – current portion 43 68 Other accrued expenses 540 440 Total accrued and other liabilities $ 5,843 $ 5,320

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES Leases The Company leases its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements in California; Pennsylvania; Fremantle, Australia; and Stockholm, Sweden. The lease for the Company’s facility in Vienna, Austria is on a month-to-month basis. The leases expire at various dates through 2020. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. Rent expense under the non-cancelable operating leases were $0.4 million and $0.3 million for the three months ended March 31, 2017 and 2016, respectively. Future minimum lease commitments under these operating and capital leases at March 31, 2017, are as follows (in thousands): Years Ending December 31, Capital Leases Operating Leases Remainder of 2017 $ 39 $ 1,615 2018 24 2,060 2019 5 2,017 2020 — 1,994 2021 — 1 Total future minimum lease payments $ 68 $ 7,687 The current portion of obligations under capital leases is included in accrued and other liabilities on the balance sheets. The long-term portion is included in other liabilities on the balance sheets. See Note 11 for the aggregate annual payment schedule for the Company’s outstanding debt. Royalty Commitments In November 2004, the Company entered into a license agreement with Roche Molecular Systems, Inc. (“Roche”) pursuant to which Roche granted the Company the right to use certain Roche technology relating to polymerase chain reaction (“PCR”), and quantitative real-time PCR, in clinical laboratory services, including in connection with AlloMap. This is a non-exclusive license agreement in the United States covering claims in multiple Roche patents. The Company had disputed the combination services percentage Roche sought to apply under the agreement. The combination service percentage is a multiplier used to calculate royalties where licensed services are sold in combination with other services. From July 2011 through September 2014, the Company withheld payment of such royalties pending resolution of the matter. On February 11, 2014, Roche filed a demand for arbitration with the American Arbitration Association seeking a declaration that the Company had materially breached the Roche license agreement by failing to report and pay royalties owing to Roche in respect of licensed services performed by the Company after July 1, 2011. Since July 1, 2011, the Company fully accrued the unpaid royalties on the balance sheets, and the amount of the unpaid royalties has been reflected as an expense in the Company’s income statements in the periods to which the royalties relate. In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby: (i) for the period beginning July 1, 2011 through June 30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii) for the period beginning July 1, 2014 through September 30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii) for the period beginning October 1, 2014 through September 30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv) the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v) Roche agreed that, subject to the Company’s timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September 30, 2017; (vi) the Company and Roche agreed to mutually release all claims under the license agreement through the settlement date; and (vii) Roche agreed to dismiss the arbitration claims. For all time periods, the contractual royalty rate in the license agreement was or will be applied to the applicable combination services percentage to determine the royalties payable to Roche in connection with the AlloMap service. Under the license agreement, the Company incurs royalty expenses as a percentage of combination services revenue and classifies those expenses as a component of cost of testing in the condensed consolidated statements of operations. Royalty expenses in connection with the Roche agreement were $0.3 million and $0.2 million for the three months ended March 31, 2017 and 2016, respectively, and are recorded as a component of cost of testing in the statement of operations. Litigation On April 25, 2016, Oberland filed a breach of contract claim against the Company in the Supreme Court of the State of New York, County of New York (the “Complaint”). Oberland alleged, among other things, that the Company breached certain provisions of the amended and restated commitment letter and the restated fee letter that it entered into with Oberland on February 8, 2016. Pursuant to the Complaint, Oberland sought damages against the Company in the amount of at least $1.4 million, plus costs and expenses, including the fees and expenses of Oberland’s attorneys. As a result, the Company previously accrued the amount being claimed by Oberland of $1.4 million. On July 15, 2016, the Company filed an answer and made counterclaims against Oberland (the “Answer”), generally denying the claims asserted by Oberland in the Complaint and asserting fraudulent inducement and breach of contract counterclaims against Oberland. Pursuant to the Answer, the Company sought dismissal of the Complaint in its entirety, rescission of all agreements with Oberland and damages of not less than $1.3 million, together with interest and punitive damages, if deemed appropriate under applicable law, and costs and disbursements of the action, including reasonable attorneys’ fees. Effective as of March 2, 2017, the Company and Oberland settled the matters covered by the Complaint and the Answer (the “Settlement”). Pursuant to the Settlement, the Company paid Oberland $0.6 million in March 2017 and each party agreed to release all claims asserted in the Complaint and the Answer. Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, would have a material adverse effect on the Company’s business, financial condition, or results of operations. On June 15, 2016, the Company received a letter from Nasdaq OMX Stockholm AB, or Nasdaq Stockholm, regarding the Company’s compliance with the requirements of the Nasdaq Stockholm Takeover Rules, or the Takeover Rules, and good practice in the securities market in Sweden in connection with the Company’s recently completed acquisition of Allenex. Nasdaq Stockholm concluded that the Company violated certain technical provisions of the Takeover Rules and acted contrary to good practice in the securities market in Sweden. On December 21, 2016, the Disciplinary Committee informed the Company that it decided to impose a SEK 1.0 million (approximately $0.1 million) fine and this amount was paid by the Company in February 2017.

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration and Licensing Agreements	10. COLLABORATION AND LICENSING AGREEMENTS Diaxonhit In June 2013, the Company entered into an exclusive Distribution and Licensing Agreement with Diaxonhit, a French public company, whereby Diaxonhit agreed to have the AlloMap test performed in a European laboratory and commercialize the test in the European Economic Area (“EEA”). The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. Consideration under the agreement included an upfront cash payment of approximately €387,500 ($414,000) that is designated to offset royalties earned by the Company in the first three years following the first commercial sale. The Company is entitled to receive royalties from Diaxonhit as a percentage of net sales, as defined in the agreement, of AlloMap tests in the mid to high teens. Approximately €250,000 ($267,000) of the upfront payments is refundable under certain circumstances. Upon confirmation that the CE mark was in place, the Company also received an equity payment of Diaxonhit common stock with a value of €387,500 ($414,000). The CE mark is a mandatory conformity marking for certain products sold within the EEA. The Company sold the shares of common stock in July 2013 for total consideration of $467,000. Other consideration that may be earned by the Company includes agreed-upon per unit pricing for the supply of AlloMap products, and additional royalties that are payable upon the achievement of various sales milestones by Diaxonhit. In this arrangement, there is one combined unit of accounting. Commercial sales of the AlloMap test began in the EEA in June 2014. Total revenues and royalties recognized from this arrangement for the three months ended March 31, 2017 and 2016 were zero and $2,000, respectively. CardioDx, Inc. In 2005, the Company entered into a services agreement with what at the time was a related party, CardioDx, Inc. (“CDX”), whereby the Company provided CDX with biological samples and related data and performed laboratory services on behalf of CDX. Each company granted the other a worldwide license to certain of its intellectual property rights. Pursuant to this agreement, CDX pays royalties to the Company in an amount equal to a low single-digit percentage of the cash collected from sales of CDX licensed products. In 2009, CDX terminated the services portion of this agreement, however, the royalty obligation from CDX continues until the tenth anniversary of the first commercial sale of a CDX licensed product. The first commercial sale of such product by CDX occurred in 2009, therefore the royalty obligation to the Company continues until 2019. Initially, the Company recognized royalty revenues when earned. Commencing with the fourth quarter of 2015, the Company recognizes royalty revenues when payments are received as it was assessed that collection was not reasonably assured prior to receipt of payment. Royalty revenues for the three months ended March 31, 2017 and 2016 were zero and $96,000, respectively, and are included in collaboration and license revenue on the condensed consolidated statements of operations. The Company had no receivable balance from CDX at March 31, 2017 and December 31, 2016.

Debt

Debt	3 Months Ended
	Mar. 31, 2017
Transfers And Servicing [Abstract]
Debt	11. DEBT Debt consisted of the following (in thousands): March 31, December JGB Debt $ 20,922 $ — East West Bank Loan — 12,614 Danske Bank Credit Facility 7,434 7,376 FastPartner Subordinated Promissory Notes 1,724 1,692 Al Amoudi Subordinated Promissory Notes 1,187 1,164 SSP Primers Loan 1,119 — Current portion of long-term debt $ 32,386 $ 22,846 SSP Primers Loan $ — $ 1,098 Long-term debt, net of current portion $ — $ 1,098 JGB Collateral LLC (“JGB”) On March 15, 2017, the Company entered into a Securities Purchase Agreement (the “SPA”) with JGB pursuant to which the Company issued Senior Secured Debentures with an aggregate principal amount of $27.8 million (the “Debentures”) and warrants (the “Warrants”) to purchase up to an aggregate of 1,250,000 shares of the Company’s common stock for net proceeds of $24.0 million (the “Financing”). The Company used $11.2 million of the net proceeds from the Financing to repay its existing indebtedness under the Loan Agreement with East West Bank and is required to maintain restricted cash of $9.4 million. The Debentures mature on February 28, 2020, accrue interest at 9.5% per year and are convertible into an aggregate of approximately 6,092,105 shares of the Company’s common stock at a price of $4.56 per share (the “Conversion Price”), which is subject to adjustment for accrued and interest and upon the occurrence of certain transactions, at the holder’s option. Additionally, after September 1, 2017, upon the satisfaction of certain conditions, including the volume weighted average price of the Company’s common stock exceeding 250% of the Conversion Price for twenty consecutive trading days, the Company can require that the Debentures be converted into shares of the Company’s common stock, subject to certain limitations. Commencing on March 1, 2018, each of the holders of the Debentures shall have the right, at its option, to require the Company to redeem up to $937,500 of the outstanding principal amount of its Debenture per month. The Company will be required to promptly, but in any event no more than one trading day after the holder delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company’s election and subject to certain conditions, in shares of the Company’s common stock. If the Company elects to pay the redemption amount in shares of the Company’s common stock, then the shares will be delivered based on a price equal to the lowest of (a) 88% of the average of the three lowest volume weighted average prices of the Company’s common stock over the prior 20 trading days, (b) 88% of the prior trading day’s volume weighted average price, or (c) the Conversion Price. After either a change of control transaction, as defined in the Debentures, or February 28, 2018, subject to the satisfaction of certain conditions, the Company may redeem all of the then outstanding principal amount of the Debentures for cash by paying the outstanding principal balance, accrued and unpaid interest, and a payment premium. The payment premium will be calculated by multiplying the outstanding balance and the following percentage: (i) 15% if the Debentures are prepaid on or prior to March 1, 2018, (ii) 8% if the Debentures are prepaid after March 1, 2018 but prior to March 1, 2019, and (iii) 5% if the Debentures are prepaid on or after March 1, 2019. The Company’s obligations under the Debentures can be accelerated upon the occurrence of certain events of default as specified in the agreement. In the event of default and acceleration of the Company’s obligations, the Company would be required to pay (i) 115% of all amounts of principal and interest then outstanding under the Debentures in cash if the Debenture is accelerated prior to March 1, 2018, (ii) 108% of all amounts of principal and interest then outstanding under the Debentures in cash if the Debenture is accelerated after March 1, 2018, but prior to March 1, 2019, and (iii) 105% of all amounts of principal and interest then outstanding under the Debentures in cash if the Debenture is accelerated after March 1, 2019. The Company’s obligations under the Debentures are secured under a Security Agreement by a senior lien on all of the Company’s assets, other than its interest in CareDx International AB (formerly known as Allenex AB), which is subject to a negative pledge prohibiting the incurrence of additional or replacement debt. The Debentures contain customary affirmative and restrictive covenants and representations and warranties, including financial reporting obligations, a restriction on the Company’s ability to pay cash dividends on its common stock and limitations on indebtedness, liens, investments, distributions, transfers, corporate changes, deposit accounts and subsidiaries. The Company must also maintain a minimum cash amount at all times, achieve commercialization of AlloSure by a certain date and achieve certain gross profit targets for sales of its AlloMap product. In connection with the Financing, on March 15, 2017, the Company and the Purchasers entered into a Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which, among other things, the Company agreed to prepare and file one or more registration statements with the Securities and Exchange Commission for the purpose of registering for resale any shares of Common Stock that may be issued by the Company upon the conversion or redemption of the Debentures or the exercise of the Warrants. The Debentures include certain embedded derivatives that require bifurcation, including settlement and penalty provisions. The compound embedded derivative will be re-measured at each reporting period and the change in fair value will be recognized in the consolidated statement of operations. See also Note 4, “Fair Value Measurements”. Loan Agreement with East West Bank On January 30, 2015, the Company entered into the Loan Agreement with East West Bank as the lender (“the Lender”), which provided the Company with a secured term loan facility in an aggregate principal amount of up to $20.0 million. The balance at March 31, 2017 and December 31, 2016 was zero and $12.6 million, respectively. In March 2017, the Company repaid the amounts outstanding under the loan agreement of $11.2 million. A fully non-refundable commitment fee of $160,000 was paid on January 30, 2015 when Draw A was received. The loan had no prepayment penalty. Commitment fees are included in debt issuance costs which are netted against the debt outstanding and are amortized to interest expense using the effective interest method over the term of the loan. Debt extinguishment charges of $0.2 million for the three-month period ended March 31,2017, were recorded in other expense on the Company’s condensed consolidated statement of operations. In connection with the Loan Agreement, the Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. The fair value of the warrant is reflected as a discount to the debt. As a result of Draw A, the Company issued to the Lender a warrant to purchase an aggregate of 34,483 shares of the Company’s common stock, at an exercise price of $6.96 per share. The fair value of the warrant was estimated to be $90,000 on January 30, 2015, using the Black-Scholes Model with the following assumptions: expected volatility of 39.83%, a contractual term of 5 years, risk-free interest rate of 1.18%, underlying common stock price of $7.06, and dividend yield of 0%. The warrant is included in stockholders’ equity. The warrant is not subject to remeasurement. The Loan Agreement required collateral by a security interest in all of the Company’s assets and contained customary affirmative and negative covenants including financial maintenance covenants, and also included standard events of default, including payment defaults. As of December 31, 2016, the Company was in compliance with its debt covenants under the Loan Agreement. Danske Bank Credit Facility On June 25, 2013, Allenex entered into the Term Loan Facility with Danske in an aggregate principal amount of up to SEK 71,000,000 (approximately $7.9 million in U.S. dollars). The Term Loan Facility is available for utilization in advances of a minimum of SEK 5,000,000 (approximately $0.6 million in U.S. dollars) and if more, integral multiples of SEK 1,000,000 (approximately $0.1 million in U.S. dollars). The interest rate applicable to each advance shall be the percentage rate per annum calculated as the aggregate of (i) Stockholm Interbank Offered Rate (“STIBOR”) (as defined in the Term Loan Facility) and (ii) the Margin (as described in the Term Loan Facility) at 3% conditional on the fulfillment of certain criteria. In March 2015, Allenex entered into a first amendment to the Term Loan Facility, pursuant to which additional loans were granted. In August 2015, Allenex entered into a second amendment to the Term Loan Facility, pursuant to which the term of the Term Loan Facility was extended. In December 2015, Allenex entered into a waiver and amendment agreement relating to the Term Loan Facility, pursuant to which the change of control provision was waived and amended. In March 2016, Allenex entered into another amendment to the Term Loan Facility, which modified the repayment schedule for advances under the Term Loan Facility. Under this Term Loan Facility, SEK 62,000,000 (approximately $6.9 million in U.S. dollars) was outstanding as of March 31, 2017, and this will be paid through quarterly payments of SEK 3,000,000, or $0.3 million in September and December of 2017 and March and June of 2018. The remaining balance of SEK 50,000,000, or approximately $5.6 million in U.S. dollars) is due in June 2018. On June 18, 2015, Allenex also entered into a short term credit facility with Danske with total available credit of SEK 8,000,000 (approximately $0.9 million in U.S. dollars). As of August 4, 2016, the available credit under the short term credit facility with Danske was increased to SEK 10,000,000 (approximately $1.1 million in U.S. dollars). As of March 31, 2017, the total outstanding balance due to Danske under the short term credit facility was SEK 4,400,000 (approximately $0.5 million in U.S. dollars), and pursuant to a quarterly roll-over provision is due on June 30, 2017. A quarterly debt covenant in the Term Loan Facility relating to maintaining an adequate leverage ratio was violated in June 30, 2016 and September 30, 2016. The Company obtained waivers from Danske for the violations of the debt covenant at June 30, 2016 and September 30, 2016. The debt covenant leverage ratio for December 31, 2016, and future periods, was amended on March 27, 2017. The Company was in compliance with the amended debt covenants at December 31, 2016. FastPartner Subordinated Promissory Notes On June 28, 2013, Allenex issued a SEK 9,400,000 (approximately $1.1 million in U.S. dollars) subordinated promissory note to FastPartner AB (“FastPartner”), which provides for an annual interest rate of 10.00%. Principal payments of SEK 1,000,000 (approximately $0.1 million in U.S. dollars) and accrued interest are payable quarterly at September 30, December 31, March 31 and June 30 and subject to working capital requirements that had not been met in fiscal years 2016 and 2015. The full amount of the promissory note was outstanding as of March 31, 2017 and December 31, 2016 and is due July 1, 2017. However, pursuant to an intercreditor agreement among Allenex, Danske, FastPartner, Mohammed Al Amoudi and Olerup SSP AB, dated June 25, 2013 (the “Intercreditor Agreement”), until the Term Loan Facility with Danske is repaid, FastPartner may not demand or receive payment of its subordinated promissory note, or foreclose on any collateral securing Allenex’s obligations under the subordinated promissory note, without Danske’s prior written consent. Allenex’s obligations under the promissory note are secured by a pledge of Allenex shares to FastPartner. On December 29, 2015, Allenex issued a SEK 2,000,000 (approximately $0.2 million in U.S. dollars) subordinated promissory note to FastPartner, a related party, which had an initial maturity date of December 31, 2016 and has an annual interest rate of 10.00%. Principal and accrued interest are payable on the maturity date and subject to working capital requirements that had not been met in fiscal years 2016 and 2015. However, pursuant to the Intercreditor Agreement, until the Term Loan Facility with Danske is repaid, FastPartner may not demand or receive payment of its subordinated promissory note, or foreclose on any collateral securing Allenex’s obligations under the subordinated promissory note, without Danske’s prior written consent. Allenex’s obligations under the promissory note are secured by a pledge of Allenex shares to FastPartner. The full amount of subordinated promissory note was outstanding as of March 31, 2017 and December 31, 2016 and is due July 1, 2017. On March 7, 2016, Allenex issued a SEK 4,000,000 (approximately $0.4 million in U.S. dollars) subordinated promissory note to FastPartner, a related party, which had an initial maturity date of December 31, 2016 and has an annual interest rate of 10.00%. Principal and accrued interest are payable on the maturity date and subject to working capital requirements that had not been met during the year ended December 31, 2016. However, pursuant to the Intercreditor Agreement, until the Term Loan Facility with Danske is repaid, FastPartner may not demand or receive payment of its subordinated promissory note, or foreclose on any collateral securing Allenex’s obligations under the subordinated promissory note, without Danske’s prior written consent. Allenex’s obligations under the promissory note are secured by a pledge of Allenex shares to FastPartner. The full amount of the subordinated promissory note was outstanding as of March 31, 2017 and December 31, 2016 and is due July 1, 2017. FastPartner is also a shareholder of the Company and is considered a related party (See Note 17). Mohammed Al Amoudi Subordinated Promissory Note On June 28, 2013, Allenex issued a SEK 10,600,000 (approximately $1.2 million in U.S. dollars) subordinated promissory note to Mohammed Al Amoudi, which provides for an annual interest rate of 10.00%. Principal payments of SEK 1,000,000 (approximately $0.1 million in U.S. dollars) and accrued interest are payable quarterly at September 30, December 31, March 31 and June 30, subject to meeting certain requirements for working capital. The promissory note had an initial maturity date of June 28, 2016. On December 31, 2016, the maturity date was extended until July 1, 2017. However, pursuant to the Intercreditor Agreement, until the Term Loan Facility with Danske is repaid, Mohammed Al Amoudi may not demand or receive payment of his subordinated promissory note, or foreclose on any collateral securing Allenex’s obligations under the subordinated promissory note, without Danske’s prior written consent. The full amount of the promissory note was outstanding as of March 31, 2017 and December 31, 2016. Allenex’s obligations under the promissory note are secured by a pledge of Allenex shares to Mohammed Al Amoudi. Mohammed Al Amoudi is also a shareholder of the Company and is considered a related party (See Note 17). Loan Agreement with SSP Primers Aktieboulag On February 25, 2015, Allenex entered into a SEK 14,000,000 (approximately $1.6 million in U.S. dollars) loan agreement with SSP Primers Aktieboulag, pursuant to which SEK 4,000,000 (approximately $0.4 million in U.S. dollars) was paid on March 7, 2016 and SEK 10,000,000 (approximately $1.1 million in U.S. dollars) is payable on February 28, 2018. The loan amount outstanding as of March 31, 2017 and December 31, 2016 is SEK 10,000,000 (approximately $1.1 million in U.S. dollars) and has an annual interest rate of 3% payable in conjunction with each principal payment. Total interest accrual on debt as of each of March 31, 2017 and December 31, 2016 was $0.8 million, respectively. As of March 31, 2017, future debt maturities were as follows (in thousands): Years Ending December 31, Amount Remainder of 2017 $ 4,076 2018 16,763 2019 11,250 2020 7,155 Total debt maturities 39,244 Less: debt discount and issuance costs (6,858 ) Total debt maturities, net of debt discount and issuance costs 32,386 Less: current portion of long-term debt (32,386 ) Long-term debt, net carrying value $ —

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity	12. STOCKHOLDERS’ EQUITY On April 14, 2016, the Company completed a Private Placement transaction for the offering of 591,860 units (“Units”) to certain accredited investors (the “Private Placement”). Each Unit was comprised of: (i) one share of common stock, (ii) five shares of Series A Preferred, and (iii) three warrants, each to purchase one share of common stock. The purchase price was $23.94 per Unit (the equivalent of $3.99 per share of common stock, assuming conversion of the Series A Preferred). The closing of the Private Placement was conditioned upon the closing of the Allenex acquisition, the consent of East West Bank to the Allenex acquisition, and certain other customary closing conditions, all of which occurred on April 14, 2016. The aggregate gross proceeds to the Company from the Private Placement were approximately $14.2 million, of which $1.8 million was paid in satisfaction of placement agents, escrow agent, legal fees as well as other direct issuance costs. The Company and certain stockholders representing a majority of the Company’s outstanding shares of common stock entered into voting agreements on April 14, 2016, pursuant to which each stockholder agreed to vote certain of its shares of the Company’s common stock in favor of granting the Company the Requisite Stockholder Approval. The proceeds from the Private Placement were allocated between the common stock, preferred stock and warrants issued based on their relative fair values. The estimated fair values of the common stock, preferred stock and warrants were $1.9 million, $9.3 million and $3.0 million, respectively, as of the transaction date. The warrants were recorded as a liability and are subject to ongoing remeasurement. The shares of Series A Preferred were initially recorded as temporary equity upon the closing of the Private Placement and subsequently reclassified to common stock after their conversion to common stock on June 16, 2016. See Note 13 for a description of the accounting of for the warrants. Concurrent to the Private Placement, the Company also entered into Commitment Letters pursuant to which the Majority Shareholders agreed to purchase the Company’s equity securities in the Subsequent Financing (as described in Note 1), which investment was completed on June 15, 2016. In the Subsequent Financing, the Company issued to the Majority Shareholders 334,169 Units, which consisted of (i) an aggregate of 334,169 shares of common stock, (ii) an aggregate of 1,670,845 shares of Series A Preferred that were all converted into shares of the Company’s common stock upon obtaining the Requisite Stockholder Approval on June 16, 2016, and (iii) 1,002,507 warrants, each of which is exercisable for one share of the Company’s common stock. The aggregate gross proceeds to the Company from the Subsequent Financing were $8.0 million. The proceeds from the Subsequent Financing were allocated between the common stock, preferred stock and warrants issued based on their relative fair values. The estimated fair values of the common stock, preferred stock and warrants were $1.0 million, $5.3 million and $1.7 million, respectively, as of the transaction date. The warrants were recorded as a liability and are subject to ongoing remeasurement. The shares of Series A Preferred were initially recorded as temporary equity upon the closing of the Subsequent Financing and subsequently reclassified to common stock after their conversion to common stock on June 16, 2016. Following the closing of the Private Placement, the Company agreed to a number of requirements, including submitting the Private Placement to the Company’s stockholders for approval, which was obtained on June 16, 2016, and granting certain registration rights, including the registration of shares sold in the Private Placement on a registration statement on Form S-3. On May 27, 2016, the Company filed a registration statement on Form S-3 with the SEC to register for resale the shares of common stock issued or issuable upon conversion of the Series A Preferred and upon exercise of the warrants sold in the Private Placement. The registration statement on Form S-3 was declared effective by the SEC on July 12, 2016. Upon obtaining the Requisite Stockholder Approval on June 16, 2016, each share of Series A Preferred was converted into one share of the Company’s common stock. In addition to the warrants issued to certain accredited investors in the Private Placement, on April 14, 2016, the Company issued warrants to purchase an aggregate of 200,000 shares of common stock to certain of its placement agents (the “Placement Agent Warrants”). All of the warrants issued in the Private Placement and the Placement Agent Warrants became exercisable once the Company obtained the Requisite Stockholder Approval on June 16, 2016. The Company engaged M.M. Dillon & Co. Group (“M.M. Dillon”), an investment banking firm, to act as one of its financial advisors and placement agents in connection with the Private Placement and Subsequent Financing of the Company’s common stock and the consummation of any private placement of its securities that the Company may choose to pursue. A member of the Company’s board of directors is a managing director of M.M. Dillon, and as such, the Company considered M.M. Dillon to be a related party. As a result of the Private Placement and Subsequent Financing, the Company paid approximately $1.1 million in placement fees to its placement agents, of which $0.2 million pertained to fees paid to M.M. Dillon. Additionally, M.M. Dillon also received Placement Agent Warrants to purchase 100,000 shares of the Company’s common stock. On September 26, 2016, the Company completed the Public Offering pursuant to which the Company issued and sold an aggregate of 2,250,000 shares of common stock at a public offering price of $4.00 per share. The aggregate gross proceeds were $9.0 million, and $7.8 million net of issuance costs. In connection with the Public Offering, in accordance with the anti-dilution provisions in the warrants issued in connection with the Private Placement and the Subsequent Financing, the exercise price of the 1,775,580 and 1,002,507 Private Placement and Subsequent Financing warrants, respectively, was adjusted from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2017
Warrants [Abstract]
Warrants	13. WARRANTS Private Placement, Placement Agent and Subsequent Financing Warrants The warrants issued in the Private Placement and the Placement Agent Warrants (as described in Note 12) are considered free standing instruments that are contingently redeemable and classified as liabilities on the Company’s condensed consolidated balance sheet as of March 31, 2017. The warrants became exercisable to purchase common stock after the Company obtained the Requisite Stockholder Approval on June 16, 2016. Upon the closing of the Private Placement on April 14, 2016, the Company recorded an estimated fair value of $3.3 million relating to warrants to purchase 1,975,580 shares of common stock that were issued in the Private Placement. The warrants were comprised of warrants to purchase 1,775,580 shares of common stock that were issued to certain accredited investors measured at an estimated fair value of $3.0 million, and Placement Agent Warrants to purchase 200,000 shares of common stock measured at an estimated fair value of $0.3 million. The Placement Agent Warrants were issued for services performed by placement agents as part of the Private Placement and were treated as equity issuance costs and were recorded in stockholders’ equity on the Company’s condensed consolidated balance sheets to offset the Private Placement proceeds allocated to the Series A Preferred and common stock. Additional warrants were issued on June 15, 2016 to the Majority Shareholders upon the closing of the Subsequent Financing (as described in Note 12). The warrants issued in the Subsequent Financing were also considered free standing instruments being accounted for using the same methodology as described above. On June 15, 2016, the Company recorded an estimated fair value of $1.7 million for warrants to purchase an aggregate of 1,002,507 shares of common stock issued in the Subsequent Financing. The initial total estimated fair value of the warrant liability was $5.0 million following the closing of the Private Placement, the issuance of Placement Agent Warrants and the closing of the Subsequent Financing. As of December 31, 2016 the total estimated fair value of the warrant liability was $5.2 million and as of March 31, 2017, the total estimated fair value of the warrant liability was $2.3 million. The corresponding remeasurement income of $3.0 million for the three-month period ended March 31, 2017, was recorded in change in estimated fair value of common stock warrant and derivative liabilities on the Company’s condensed consolidated statement of operations. JGB Debt Warrants In connection with the issuance of the JGB debt (as described in Note 11), the Company issued warrants to purchase up to an aggregate of 1,250,000 shares of the Company’s common stock. The exercise price of the warrants is $5.00 per share, and the warrants are exercisable from September 16, 2017 through September 15, 2022. The initial estimated fair value of the warrant liability was $0.9 million. As of March 31, 2017, the estimated fair value of the warrant liability was $0.5 million and the corresponding remeasurement income of $0.4 million for the three-month period ended March 31, 2017 was recorded in change in estimated fair value of common stock warrant and derivative liabilities on the Company’s condensed consolidated statement of operations. The Company determined that the warrants and the Debentures were free standing instruments for accounting purposes. The terms of the warrants include a down round protection, which precludes the Company from classifying the warrants in equity. As such, the warrants are classified as a liability and allocated their full fair value on day one and the residual value, after allocation of the fair value of the derivative is ascribed to the Debentures. In addition, the warrants will be re-measured at each reporting period and change in fair value will be recognized in the consolidated statement of operations. See also Note 4, “Fair Value Measurements”. Warrant Valuation The Company utilizes a Monte Carlo simulation model to estimate the fair value of its warrants. The Monte Carlo simulation model uses multiple input variables to estimate the probability that market conditions will be achieved. These variables include the Company’s stock price, the expected term of the warrants, the volatility of the Company’s and its peers’ stock prices over such expected term, and the risk-free interest rate for the expected term of the warrants. The variables used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. If the Company issues common stock at a price lower than the exercise price or issues stock options or other securities (other than securities issued pursuant to the Company’s stock or option plans or employment agreements, securities issued or issuable upon exercise or exchange of convertible securities outstanding as of the date the warrants were issued or securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company) with an exercise price that is lower than the current exercise price of the warrants, the exercise price of the warrants shall be adjusted to be equal to such lower price. As a result of the anti-dilution provisions in the warrants issued in connection with the Private Placement and the Subsequent Financing, the exercise price of the 1,775,580 and 1,002,507 Private Placement and Subsequent Financing warrants, respectively, was adjusted from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering. The number of warrants outstanding did not change. As of March 31, 2017, outstanding warrants to purchase Common Stock were: Original Term Exercise Price Number of Shares Underlying Warrants Original issue date: February 2008 10 years $ 35.10 22,792 August 2009 10 years $ 21.78 33,473 July 2010 9 years $ 21.78 6,694 December 2010 7 years $ 21.78 17,215 August 2012 7 years $ 21.78 167,182 January 2015 5 years $ 6.96 34,483 April 2016 (a) 7 years $ 4.00 1,775,580 April 2016 (b) 5 years $ 3.99 200,000 June 2016 (c) 7 years $ 4.00 1,002,507 March 2017 (d) 5 years $ 5.00 1,250,000 4,509,926 (a) Issued on April 14, 2016 in connection with the Private Placement to certain accredited investors. The exercise price was reset from $4.98 to $4.00 as a result of the Public Offering that closed on September 26, 2016. In accordance with the anti-dilution provisions, the exercise price of the warrants issued in connection with the Private Placement reset from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering, which closed on September 26, 2016. (b) Issued on April 14, 2016 in connection with the Private Placement to placement agents. (c) Issued on June 15, 2016 in connection with the Subsequent Financing. The exercise price was reset from $4.98 to $4.00 as a result of the Public Offering that closed on September 26, 2016. In accordance with the anti-dilution provisions, the exercise price of the warrants issued in connection with the Subsequent Financing reset from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering, which closed on September 26, 2016. (d) Issued on March 15, 2017 in connection with JGB Debt.

Stock Incentive Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Incentive Plans	14. STOCK INCENTIVE PLANS 2014 Equity Incentive Plan Prior to its IPO in July 2014, the Company had one active stock option plan, the 2008 Equity Incentive Plan (“2008 Plan”), one assumed stock option plan (the “ImmuMetrix 2013 Equity Incentive Plan”) and one terminated stock option plan, the 1998 Stock Plan. Upon its IPO, the Company reserved 838,695 shares of common stock for issuance under a new 2014 Equity Incentive Plan (“2014 Plan”). The shares reserved for issuance under the 2014 Plan also include shares returned to the 2008 Plan as the result of expiration or termination of options, provided that the maximum number of shares that may be added to the 2014 Plan thereby is limited to a maximum of 865,252 shares. The number of shares available for issuance under the 2014 Plan will also include an annual increase on the first day of each year beginning in 2014, equal to the least of: • 357,075 shares; • 4.0% of the outstanding shares of common stock as of the last day of the immediately preceding year; or • such other number of shares as the Company’s board of directors may determine. 2016 Inducement Plan On April 21, 2016, the Company’s board of directors, including its independent directors, adopted the Company’s 2016 Inducement Equity Incentive Plan (the “Inducement Plan”), pursuant to which the Company may grant stock awards of up to a total of 155,500 shares of common stock to new employees of the Company. The Inducement Plan was adopted to accommodate a reserve of additional shares of common stock for issuance to new employees hired by the Company from Allenex. The terms in the Inducement Plan are substantially similar to the Company’s 2014 Plan. The Inducement Plan allows restricted stock units (“RSUs”) to be granted in addition to stock options. The RSUs vest annually over four years in equal increments. The Company began granting RSUs pursuant to the Inducement Plan starting June 2016. Stock Options and Restricted Stock Units (“RSUs”) The following table summarizes option and unvested RSU activity under the plans and related information: Shares Available for Grant Stock Options Outstanding Weighted- Average Exercise Price Number of RSU Shares Weighted- Average Grant Date Fair Value Balance—December 31, 2016 365,074 1,792,286 $ 6.15 306,245 $ 5.69 Additional options authorized 357,075 — — Restricted stock grants (21,214 ) — — RSUs granted (182,500 ) — 182,500 2.30 RSUs forfeited 8,157 — (8,157 ) 5.46 RSUs vested — — (39,678 ) 5.75 Options granted (250,100 ) 250,100 2.33 — Options exercised — — — Options forfeited 26,668 (26,668 ) 8.63 — Options expired 26,140 (26,140 ) 6.75 — Balance—March 31, 2017 329,300 1,989,578 $ 5.62 440,910 $ 4.29 The total intrinsic value of options exercised was zero during the three months ended March 31, 2017. As of March 31, 2017, the total intrinsic value of RSUs was approximately $617,000 and there were $21.0 million of unrecognized compensation costs related to RSUs, which are expected to be recognized over a weighted-average period of 3.08 years. Options outstanding that have vested or are expected to vest as of March 31, 2017 are as follows: Number of Shares Weighted Exercise Price Weighted Aggregate Intrinsic (In Vested 1,091,452 $ 6.01 6.54 $ 165 Expected to vest 789,964 5.17 8.85 — Total 1,881,416 $ 5.66 7.51 $ 165 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock at March 31, 2017 for stock options that were in-the-money. The fair market value of the Company’s common stock as of March 31, 2017 was $1.40 per share. The weighted average grant-date fair value of options to purchase common stock granted during the three months ended March 31, 2017 and 2016 using the Black-Scholes Model was $1.20 and $2.07, respectively. The Company uses the grant date fair value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company’s common stock as of the last day of each reporting period. The total fair value of options that vested during the three months ended March 31, 2017 was $0.4 million. As of March 31, 2017, there were approximately $1.8 million of unrecognized compensation costs related to stock options, which are expected to be recognized over a weighted-average period of 2.32 years. The Company’s 2014 Plan and Inducement Plan allow RSUs to be granted in addition to stock options. The RSUs vest annually over four years in equal increments. The Company began granting RSUs under the 2014 Plan in March 2015 and under the Inducement Plan in June 2016. 2014 Employee Stock Purchase Plan The Company’s board of directors adopted its 2014 Employee Stock Purchase Plan (the “ESPP”) in March 2014 and its stockholders approved the ESPP in July 2014. The first offering period of the ESPP began on January 1, 2015 and ended June 30, 2015. The first offering period in 2017 began on January 1, 2017 and will end on June 30, 2017. During the second offering period in 2016 that ended on December 31, 2016, 19,027 shares were purchased for aggregate proceeds of $44,000 from the issuance of shares, which occurred on January 10, 2017. The option price per share of common stock to be paid by a participant on the applicable exercise date for an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (a) the applicable grant date or (b) the applicable exercise date. Valuation Assumptions The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Three Months Ended March 31, 2017 2016 Employee stock options Expected term (in years) 6.0 6.0 Expected volatility 53.07% – 53.36% 39.60% – 39.69% Risk-free interest rate 2.08% – 2.12% 1.54% – 1.65% Expected dividend yield — % — % Employee stock purchase plan Expected term (in years) 0.5 0.5 Expected volatility 62.27 % 64.21 % Risk-free interest rate 0.65 % 0.49 % Expected dividend yield — % — % Stock-based Compensation Expense The following table summarizes stock-based compensation expense relating to employee and nonemployee stock options, RSUs and ESPP shares for the three months ended March 31, 2017 and 2016, included in the statements of operations as follows (in thousands): Three Months Ended March 31, 2017 2016 Cost of testing $ 55 $ 28 Research and development 64 113 Sales and marketing 38 28 General and administrative 234 277 Total $ 391 $ 446 No tax benefit was recognized related to share-based compensation expense since the Company has never reported taxable income and has established a full valuation allowance to offset all of the potential tax benefits associated with its deferred tax assets. In addition, no amounts of stock-based compensation were capitalized for the periods presented. Non-Employee Director Equity-based Compensation For the three months ended March 31, 2017 and 2016, the Company paid a portion of its non-employee directors’ compensation through the award of common shares. The stock awards are classified as equity, and compensation expense was recognized upon the issuance of the shares. As of March 31, 2017, there was a total of 126,155 shares issued to non-employee directors, for a total fair value of $620,000. Expense associated with the awards was $43,000 and $79,000 for the three months ended March 31, 2017 and 2016, respectively, which was included in general and administrative expense in the condensed consolidated statements of operations.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	15. INCOME TAXES The Company’s effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income. For the three months ended March 31, 2017, the Company recorded an income tax benefit of $0.3 million, compared to none for the three months ended March 31, 2016. In conjunction with the acquisition of Allenex on April 14, 2016, a deferred tax liability was recorded at the acquisition date for the difference between the financial reporting and tax basis of the intangible assets. This benefit primarily resulted from the reversal of the net deferred tax liabilities relating to the amortization of the intangible assets which are not deductible for tax purposes.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Reporting	16. SEGMENT REPORTING Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and types of customers served and the products or services provided in those markets. Prior to the acquisition of Allenex, the Company operated as a single reportable segment. Subsequent to the acquisition of Allenex, the Company has identified the following two reportable segments, which are the same as its operating segments: • CareDx: This segment focuses on discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. Its first commercialized testing solution, AlloMap, is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. • Olerup: This segment develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The Olerup product lines include Olerup SSP, Olerup SBT, Olerup QTYPE, Olerup SBT Resolver and Olerup XM-ONE. There were no intersegment sales for the three months ended March 31, 2017. The following table summarizes the operating results of the Company’s reportable segments (in thousands): Three 2017 2016 Total segments Net revenues $ 11,584 $ 6,562 Operating loss (8,544 ) (6,569 ) Depreciation and amortization 934 261 CareDx Net revenues $ 7,917 $ 6,562 Operating loss (5,459 ) (6,569 ) Depreciation and amortization 262 261 Olerup Net revenues $ 3,667 $ — Operating loss (3,085 ) — Depreciation and amortization 672 — March 31, December Assets: CareDx $ 45,507 $ 41,169 Olerup 34,815 35,561 Total assets $ 80,322 $ 76,730 Revenues by geographic regions are based upon the customers’ ship-to address or headquarters location. The following table summarizes reportable revenues by geographic regions (in thousands): Three 2017 2016 Revenues: North America $ 8,902 $ 6,562 Europe, Middle East and Africa 2,408 — Latin America 158 — Australia 116 — Total $ 11,584 $ 6,562 The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands): March 31, December Long-lived assets: United States $ 1,843 $ 2,052 Europe 829 879 Australia 96 — Total $ 2,768 $ 2,931

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	17. RELATED PARTY TRANSACTIONS The Company has loans outstanding with both FastPartner AB and Mr. Mohammed Al Amoudi as of March 31, 2017 (as described in Note 11). A member of the Company’s board of directors is a managing director of M.M. Dillon, and as such, the Company considered M.M. Dillon to be a related party. M.M. Dillon acted as one of the Company’s financial advisors and placement agents in connection with the Private Placement and Subsequent Financing (as described in Note 12).

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	18. SUBSEQUENT EVENTS Failure to Timely File Annual Report on Form 10-K The Company did not timely file its Annual Report on Form 10-K for the year ended December 31, 2016 (the “Form 10K”), which was due on April 17, 2017. As a result, the Company is currently ineligible to file new short form registration statements on Form S-3, is unable to conduct “off the shelf” offerings under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), using its currently effective registration statement on Form S-3 (File No. 333-206277) and its resale registration statement on Form S-3 covering the sale of up to 8,534,261 shares of common stock by selling stockholders, including stockholders who acquired common stock in connection with private placements, cannot currently be used by such selling stockholders to resell such shares of common stock. In addition, the failure to timely file the Form 10-K constituted a breach of the Company’s covenant under the SPA to make all required Securities Exchange Act of 1934, as amended (the “Exchange Act”), filings with the Securities and Exchange Commission on a timely basis. The breach was cured upon the filing of Form 10-K within the required 15 trading days following the breach. Failure to Timely File Registration Statement Pursuant to the Company’s Registration Rights Agreement, dated March 15, 2017, with JGB, which was entered into in connection with the SPA and the Debentures, the Company was required to file a registration statement with the SEC registering for resale the Company’s common stock underlying the securities issued or issuable to JGB in the financing. Because the Company failed to file the registration statement with the SEC by April 17, 2017, commencing on April 18, 2017, the Company began accruing liquidated damages payable to JGB at a rate of approximately $7,000 per day. These damages accrued at the same rate on a daily basis until the registration statement was filed with the SEC on April 26, 2017. On May 3, 2017, JGB waived any claim or right to receive liquidated damages for the late filing of the registration statement. Filing of Resale Registration Statement on Form S-1 On April 26, 2017, in accordance with the Registration Rights Agreement, the Company filed a Registration Statement on Form S-1 (the “Form S-1”) registering for resale an aggregate of 8,250,000 shares of the Company’s common stock that may be issued by the Company upon the conversion or redemption of the Debentures or the exercise of the Warrants. The Form S-1 was declared effective by the SEC on May 11, 2017. Failure to Timely File Quarterly Report on Form 10-Q The Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (the “Form 10-Q”), which was due on May 22, 2017. As a result, the Company is currently ineligible to file new short form registration statements on Form S-3, is unable to conduct “off the shelf” offerings under Rule 415 of the Securities Act using its currently effective registration statement on Form S-3 (File No. 333-206277) and its resale registration statement on Form S-3 covering the sale of up to 8,534,261 shares of common stock by selling stockholders, including stockholders who acquired common stock in connection with private placements, cannot currently be used by such selling stockholders to resell such shares of common stock. In addition, the failure to timely file the Form 10-Q constituted a breach of the Company’s covenant under the SPA to make all required Exchange Act filings with the SEC on a timely basis. The breach can be cured upon the filing of Form 10-Q within the required 15 trading days following the breach.

Organization and Description 25

Organization and Description of Business (Policies)	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Liquidity And Going Concern	Liquidity and Going Concern The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) effective December 31, 2016, which requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements. The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $218.1 million at March 31, 2017. As of March 31, 2017, the Company had cash and cash of debt outstanding under its debt obligations, net of debt discount. In March 2017, the Company received net proceeds of $24.0 million in connection with the issuance of a convertible debt obligation to JGB Collateral LLC and certain of its affiliates (“JGB”), of which $11.2 million was used to repay the Company’s outstanding debt obligations to East West Bank. In addition, the debt agreement requires the Company to maintain a minimum of $9.4 million of cash at a named financial institution. These funds are restricted as to withdrawal and are not available to the Company to fund its operations or repay indebtedness. Pursuant to the Company’s convertible debt financing agreements, the Company was required to file a registration statement with the SEC registering for resale the shares underlying the securities issued or issuable to JGB in the financing. Because the Company failed to file the registration statement with the SEC by April 17, 2017, commencing on April 18, 2017, the Company began accruing liquidated damages payable to JGB at a rate of approximately $7,000 per day. These damages accrued at the same rate on a daily basis until the registration statement was filed with the SEC on April 26, 2017. On May 3, 2017, JGB waived any claim or right to receive liquidated damages for the late filing of the registration statement. A quarterly debt covenant in the Company’s Term Loan Facility Agreement (the “Term Loan Facility”) with Danske Bank A/S (“Danske”) relating to maintaining an adequate leverage ratio was violated in June 30, 2016 and September 30, 2016. The Company obtained waivers from Danske for the violations of the debt covenant at June 30, 2016 and September 30, 2016. The debt covenant leverage ratio for December 31, 2016 and future periods was amended on March 27, 2017. The Company was in compliance with the amended debt covenants at December 31, 2016. The Company believes its cash and cash equivalents of $12.2 million at March 31, 2017 and expected revenues will not be sufficient to allow the Company to fund its current operations beyond June 30, 2017. The Company will require additional financing and/or refinancing of its current debt obligations to fund working capital, repay debt and pay its obligations. The Company may pursue financing and refinancing opportunities in both the private and public debt and equity markets through sales of debt or equity securities. Additional financing might include one or more offerings and one or more of a combination of discounted or at-the-market common stock, securities convertible into or exchangeable for shares of common stock, warrants or other rights to purchase or acquire common stock. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable to the Company. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of the issuance of these financial statements. If the Company is unsuccessful in its efforts to raise additional financing and/or refinance the Company’s indebtedness in the near term, the Company will be required to significantly reduce or cease operations. Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern, the entire amount of borrowings was classified as current at March 31, 2017. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The condensed consolidated balance sheet as of December 31, 2016 has been derived from audited financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany transactions have been eliminated. Since the Company owns less than 100% of the shares of Allenex, the Company records net loss attributable to noncontrolling interest in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, including from acquisitions, (vi) inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii) any impairment of long-lived assets, including in-process technology and goodwill, and (xiii) legal contingencies. Actual results could differ from those estimates.
Concentrations of Credit Risk and Other Risks and Uncertainties	Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits. The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers, and sales of Olerup products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., Latin America and other geographic regions. The Company has not experienced any significant credit losses and does not generally require collateral on receivables.
Cash Equivalents	Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market funds.
Restricted Cash	Restricted Cash Under lease agreements for certain facilities and an agreement with the State of Florida Medicaid, the Company must maintain letters of credit, minimum collateral requirements and a surety bond. These agreements are collateralized by cash. The cash used to support these arrangements is classified as long-term restricted cash on the accompanying balance sheets. Under the Company’s convertible debt financing agreements with JGB, the Company is required to maintain restricted cash of $9.4 million, which is restricted as to withdrawal and is not available to the Company to fund its operations or repay indebtedness. The restricted cash used to support the convertible debt facility
Inventory	Inventory Inventory is finished goods, work in progress and raw materials and consist of AlloMap reagent plates, laboratory supplies, reagents, Olerup SBT kits and Olerup SSP kits. Inventories are used in connection with tests performed and may also be used for research and product development efforts. Laboratory supplies subsequently designated for research and product development use are expensed. Obsolete or damaged inventories are written off and excluded from the physical inventory. Inventories at our Stockholm, Sweden and Fremantle, Australia locations are stated at the lower of purchased cost, determined on an average cost basis, or net realizable value. Inventories at our other locations are stated at the lower of purchased cost, determined on a first-in, first-out basis or net realizable value.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, generally three years for laboratory, computer and office equipment, and generally seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of their estimated useful lives or the remaining lease term. Assets held under capital leases are recorded at the lower of the net present value of the minimum lease payments or the fair market value of the leased asset at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the assets or the period of the related lease. The Company capitalizes certain costs incurred for software developed or obtained for internal use. These costs include software licenses, consulting services, and direct materials, as well as employee payroll and payroll-related costs. Capitalized internal-use software costs are depreciated over three years.
Purchased Intangible Assets	Purchased Intangible Assets Amortizable intangible assets include customer relationships, developed technology, trademarks, contracts and in-process research and development (“IPR&D”) identified intangible assets acquired as part of a business combination. Intangible assets subject to amortization are amortized over their estimated useful lives. Acquired intangible assets with indefinite useful lives are related to IPR&D projects and are measured at their respective fair values as of the acquisition date. The Company does not amortize intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests IPR&D for impairment on an annual basis and in between annual tests if it becomes aware of events or changes that would indicate that it is more likely than not that the fair value of the assets is below their carrying amounts. The IPR&D annual impairment test is performed as of December 1 of each fiscal year. If the fair value exceeds the carrying value, then there is no impairment. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of an asset to its carrying value, without consideration of any recoverability test. The Company has not identified any such impairment losses to date.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company evaluates its long-lived assets for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The Company then compares the carrying amounts of the assets with the future net undiscounted cash flows expected to be generated by such asset. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value determined using discounted estimates of future cash flows. The Company has not identified any such impairment losses to date.
Goodwill	Goodwill Goodwill represents the excess of the cost of an acquisition over the sum of the amounts assigned to tangible and identifiable intangible assets acquired, less liabilities assumed. Goodwill is not subject to amortization, but is tested for impairment on an annual basis and whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. The Company has determined that it operates in two reportable segments associated with the delivery of diagnostic tests and the development and commercialization of diagnostic products. The reporting unit’s carrying value is compared to its fair value and an impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss should not exceed the total amount of goodwill allocated to the reporting unit. The estimated fair values of the reporting units are determined using either the market approach, income approach or a combination of the market and income approach. Goodwill is considered impaired if the carrying value of the reporting unit exceeds its estimated fair value. The income approach uses expected future operating results and failure to achieve these expected results may cause a future impairment of goodwill at the reporting unit. The Company conducted a goodwill impairment test as of March 31, 2017 and identified an impairment of $2.0 million related to the goodwill recorded in the Olerup reportable segment. See Note 6 for additional discussion regarding the impairment charge recorded.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which the Company would transact, and it takes into consideration the assumptions that market participants would use when pricing the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement of an asset or liability requires management to make judgments and to consider specific characteristics of that asset or liability. The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities. The carrying amounts of the common stock warrant liability, derivative liability and contingent consideration liability also represents their fair values.
Common Stock Warrant Liability and Derivative Liability	Common Stock On April 14, 2016 and June 15, 2016, the Company completed the Private Placement and Subsequent Financing, respectively (as described in Note 12), which included the issuance of free standing warrants to certain accredited investors and placement agents to purchase shares of the Company’s common stock. The exercisability of the warrants was contingent upon the receipt of approval of the Private Placement by the Company’s stockholders pursuant to the rules of The NASDAQ Stock Market LLC (the “Requisite Stockholder Approval”), which occurred on June 16, 2016. The free standing warrants issued pursuant to the Private Placement and Subsequent Financing are contingently redeemable and are classified as liabilities on the consolidated balance sheet and recorded at their estimated fair value. The warrants are remeasured at each balance sheet date with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability on the consolidated statements of operations. On March 15, 2017, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued Senior Secured Debentures and warrants (as described in Note 11). The Company determined that the Debentures and the warrants were free standing instruments. The terms of the warrants include a price-based anti-dilution adjustment provision, which precludes the Company from classifying the warrants in equity. As such, the warrants are classified as liabilities on the consolidated balance sheet. The full fair value of the warrants was allocated on day one to the warrant liability and the residual value, after allocation of the fair value of the derivative liability discussed below, was ascribed to the Debentures. The warrants will be re-measured at each reporting period with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability on the consolidated statements of operations. The Debentures are classified as liabilities on the consolidated balance sheet and include certain embedded derivatives that required bifurcation, including settlement and penalty provisions. The compound embedded derivative will be re-measured at each reporting period with changes recorded in change in estimated fair value of common stock warrant liability and derivative liability on the consolidated statements of operations.
Testing Revenue	Testing Revenue The Company recognizes revenues for tests delivered when the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred or services rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. For testing revenue, the first criterion is satisfied when a third-party payer makes a coverage decision or enters into a contractual arrangement with the Company for the test. The second criterion is satisfied when the Company performs the test and delivers the test result to the ordering physician. The third criterion is satisfied if the third-party payer’s coverage decision or reimbursement contract specifies a price for the test. The fourth criterion is satisfied based on management’s judgments regarding the collectability of the fees charged under the arrangement. Such judgments include review of past payment history. AlloMap testing may be considered investigational by some payers and not covered under their reimbursement policies. Others may cover the test, but not pay a set or determinable amount. As a result, in the absence of a reimbursement agreement or sufficient payment history, collectability cannot reasonably be assured so revenue is not recognized at the time the test is delivered. If all criteria set forth above are met, revenue is recognized on an accrual basis when the test is performed. When the first, third or fourth criteria are not met but third-party payers make a payment to the Company for tests performed, the Company recognizes revenue on the cash basis in the period in which the payment is received. Revenue for tests performed is recognized on the accrual basis net of adjustments for differences between amounts billed and the estimated receipts from payers. The amount the Company expects to collect may be lower than the agreed upon amount due to several factors, such as the amount of patient co-payments, the existence of secondary payers and claim denials. Estimated receipts are based upon historical payment practices of payers. Differences between estimated and actual cash receipts are recorded as an adjustment to revenue, which have been immaterial to date. Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are excluded from revenue in the statements of operations.
Product Revenue	Product Revenue Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when persuasive evidence of an arrangement exists, the product is complete and tested and has been shipped or delivered, as required to transfer title and risk of loss, the sales price is fixed and determinable, collection of the resulting receivable is reasonably assured, there are no material contingencies and the Company does not have significant obligations for future performance. When collectability is not reasonably assured, the Company defers the revenue until the cash is received. Provisions for estimated future product returns and allowances are recorded in the period of the sale based on the historical and anticipated future rate of returns. Revenue is recorded net of any discounts given to the buyer.
Collaboration, License and Other Revenue	Collaboration, License and Other Revenue The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the three months ended March 31, 2017 or 2016.
Cost of Testing and Product	Cost of Testing Cost of testing reflects the aggregate costs incurred in delivering the Company’s AlloMap test results to clinicians. The components of cost of testing are materials and service costs, direct labor costs, stock-based compensation, equipment and infrastructure expenses associated with testing samples, shipping, logistics and specimen processing charges to collect and transport samples and allocated overhead including rent, information technology, equipment depreciation, utilities and royalties. Costs associated with performing tests (except royalties) are recorded as the test is processed regardless of whether and when the testing revenue is recognized with respect to that test. As a result, the Company’s cost of testing as a percentage of revenue may vary significantly from period to period because the Company does not recognize all revenue in the period in which the associated costs are incurred. Royalties for licensed technology, calculated as a percentage of test revenues, are recorded as license fees in cost of testing at the time the test revenues are recognized. Cost of Product Cost of product reflects the aggregate costs incurred in delivering the Company’s products to customers. The components of cost of product are materials costs, manufacturing and kit assembly costs, direct labor costs, equipment and infrastructure expenses associated with preparing kitted products for shipment, shipping, and allocated overhead including rent, information technology, equipment depreciation and utilities. Cost of product also includes amortization of acquired developed technology and adjustments to inventory values, including write-down of impaired, slow moving or obsolete inventory.
Business Combinations	Business Combinations The Company determines and allocates the purchase price of an acquired business to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on independent valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rates, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods. In those circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity Transaction costs associated with acquisitions are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company’s operating results from the date of acquisition.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent costs incurred to develop new surveillance solutions as well as continued development of the Company’s AlloMap test. These expenses include payroll and related expenses, consulting expenses, laboratory supplies, and certain allocated expenses as well as amounts incurred under certain collaboration and license agreements. Research and development costs are expensed as incurred. The Company records accruals for estimated study costs comprised of work performed by contract research organizations under contract terms.
Advertising Expenses	Advertising Expenses All advertising costs are expensed as incurred. Advertising expenses were insignificant during all of the periods presented.
Stock-based Compensation	Stock-based Compensation The Company uses the Black-Scholes Model, which requires the use of estimates such as stock price volatility and expected option lives, to value employee stock options. The Company estimates the expected option lives using historical data, volatility using its own historical stock prices and stock prices of peer companies in the diagnostics industry, risk-free rates using the implied yield currently available in the U.S. Treasury zero-coupon issues with a remaining term equal to the expected option lives, and dividend yield using the Company’s expectations and historical data. The fair value of each restricted stock unit is calculated based upon the closing price of the Company’s common stock on the date of the grant. The Company uses the straight-line attribution method for recognizing compensation expense. Compensation expense is recognized on awards ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures are estimated based on the Company’s historical experience. Compensation expense for stock options issued to nonemployees is calculated using the Black-Scholes Model and is recorded over the service performance period. Options subject to vesting are required to be periodically remeasured over their service performance period, which is generally the same as the vesting period.
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company’s assessment of an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.
Foreign Currency Translation	Foreign Currency Translation The functional currency of the Company’s foreign subsidiaries is the local currency for each entity, including the Swedish Krona, Australian dollar and the Euro. The revenue and expenses of such subsidiaries have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the balance sheet date. The resulting cumulative translation adjustments are reported in other comprehensive loss. Foreign currency transaction gains and losses are recognized in current operations.
Comprehensive (Loss) Income	Comprehensive (Loss) Income Comprehensive (loss) income consists of net (loss) income and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income or loss. For the Company, such items consist of foreign currency translation losses.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”) In March 2016, the FASB issued ASU No 2016-09, Compensation - Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing . Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606), , In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force) . consolidated financial statements In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business . The Company adopted ASU No. 2017-01 on January 1, 2017 on a prospective basis and its adoption did not have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . .

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following tables set forth the computation of the Company’s basic and diluted net loss per share (in thousands, except shares and per share data): Three Months Ended March 31, 2017 2016 Numerator: Net loss attributable to CareDx, Inc. used to compute basic net loss per share $ (5,562 ) $ (9,752 ) Net loss attributable to CareDx, Inc. used to compute diluted net loss per share $ (5,562 ) $ (9,752 ) Denominator: Weighted-average shares used to compute basic net loss per share attributable to CareDx, Inc. 21,343,782 11,969,714 Weighted-average shares used to compute diluted net loss per share attributable to CareDx, Inc. 21,343,782 11,969,714 Net loss per share attributable to CareDx, Inc.: Basic $ (0.26 ) $ (0.81 ) Diluted $ (0.26 ) $ (0.81 )
Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share	The following potentially dilutive securities have been excluded from diluted net loss per share, because their effect would be antidilutive: Three Months Ended March 31, 2017 2016 Shares of common stock subject to outstanding options 1,881,416 1,860,420 Shares of common stock subject to outstanding common stock warrants 4,509,926 301,069 Shares of common stock subject to convertible notes 6,092,105 - Restricted stock units 440,910 178,975 Total common stock equivalents 12,924,357 2,340,464

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis, as of March 31, 2017 and December 31, 2016 (in thousands): March 31, 2017 Fair Value Measured Using (Level 1) (Level 2) (Level 3) Total Balance Assets Money market funds $ 11,723 $ — $ — $ 11,723 Liabilities Contingent consideration $ — $ — $ 271 $ 271 Common stock warrant liability — — 2,759 2,759 Derivative liability — — 1,510 1,510 Total liabilities $ — $ — $ 4,540 $ 4,540 December 31, 2016 Fair Value Measured Using (Level 1) (Level 2) (Level 3) Total Balance Assets Money market funds $ 14,497 $ — $ — $ 14,497 Liabilities Contingent consideration $ — $ — $ 492 $ 492 Common stock warrant liability — — 5,208 5,208 Total liabilities $ — $ — $ 5,700 $ 5,700
Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments	The following table presents the issuances, changes in fair value and reclassifications of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands): (Level 3) Contingent Consideration Liability Common Derivative Liability Total Balance as of December 31, 2016 $ 492 $ 5,208 $ — $ 5,700 Issuance of JGB debt and warrants — 900 2,290 3,190 Change in estimated fair value (221 ) (3,349 ) (780 ) (4,350 ) Balance as of March 31, 2017 $ 271 $ 2,759 $ 1,510 $ 4,540
Summary of Common Stock Warrant Liability and Derivative Liability Assumptions	Common Stock Warrant Liability and Derivative Liability Assumptions March 31, 2017 December 31, 2016 Private Placement Common Stock Warrant Liability Stock Price $ 1.40 $ 2.70 Exercise Price $ 4.00 $ 4.00 Remaining term (in years) 6.04 6.29 Volatility 54.00 % 51.40 % Risk-free interest rate 2.08 % 2.14 % Placement Agent Common Stock Warrant Liability Stock Price $ 1.40 $ 2.70 Exercise Price $ 3.99 $ 3.99 Remaining term (in years) 4.04 4.29 Volatility 60.30 % 56.10 % Risk-free interest rate 1.72 % 1.77 % March 31, 2017 March 15, 2017 JGB Common Stock Warrant Liability Stock Price $ 1.40 $ 2.15 Exercise Price $ 5.00 $ 5.00 Remaining term (in years) 5.46 5.50 Volatility 56.00 % 54.00 % Risk-free interest rate 1.98 % 2.06 % Derivative Liability Stock Price $ 1.40 $ 2.15 Remaining term (in years) 2.91 2.96 Volatility 56.00 % 54.00 % Risk-free interest rate 1.61 % 1.72 %

Business Combination (Tables)

Business Combination (Tables)	3 Months Ended
	Mar. 31, 2017
Allenex [Member]
Schedule of Noncontrolling Interests	Total Noncontrolling interest at December 31, 2016 $ 279 Foreign currency effect $ (5 ) Loss attributable to noncontrolling interest (47 ) Noncontrolling interest at March 31, 2017 $ 227
Conexio [Member]
Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed as of Acquisition Date	The following table summarizes the preliminary recording of the fair values of the assets acquired and liabilities assumed as of the acquisition date. Given the timing of the close of the transaction in the first quarter of 2017, the inventory and intangible assets amounts are preliminary and subject to change as the Company finalizes its fair value assessments (in thousands): Total Inventory $ 1,040 Property, plant and equipment 97 Intangible assets 155 Goodwill 85 Assumed liabilities (82 ) Total preliminary acquisition consideration $ 1,295
Summary of Identified Intangible Assets Acquired at Acquisition Date	The following table presents details of the identified intangible assets acquired at the acquisition date (in thousands): Estimated Fair Estimated Life (Years) Completed technology $ 127 9 Customer relationships 28 9 Total $ 155
Allenex and Conexio [Member]
Schedule of Pro Forma Results of Operations	The unaudited pro forma financial information in the table below summarizes the combined results for the Company and Allenex as if the companies were combined as of January 1, 2016. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands). Three March 31, 2016 Revenue: Testing revenue $ 6,449 Product revenue 3,860 Other revenue 191 Total revenue $ 10,500 Net loss $ (6,313 )

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Reporting Unit	The following table presents details of the Company’s goodwill by reporting unit as of March 31, 2017 (in thousands): CareDx Olerup Total Balance as of January 1, 2017 Goodwill $ 12,005 $ 14,855 $ 26,860 Accumulated impairment losses — $ (13,021 ) (13,021 ) 12,005 1,834 13,839 Goodwill acquired — 85 85 Impairment losses — (1,958 ) (1,958 ) Foreign currency translation adjustments — 39 39 Balance as of March 31, 2017 Goodwill 12,005 14,979 26,984 Accumulated impairment losses — (14,979 ) (14,979 ) $ 12,005 $ — $ 12,005
Summary of Intangible Assets	The following tables present details of the Company’s intangible assets as of March 31, 2017 (in thousands): March 31, 2017 Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Amount Weighted Average Remaining Useful (In Intangible assets with finite lives: Customer relationships: Allenex $ 12,650 $ (772 ) $ (1,151 ) $ 10,727 13.8 Customer relationships: Conexio 28 (1 ) 1 28 8.8 Customer relationships 12,678 (773 ) (1,150 ) 10,755 Developed technology: SSP 11,650 (1,076 ) (1,051 ) 9,523 8.8 Acquired technology: QTYPE 4,510 (146 ) (415 ) 3,949 13.8 Acquired technology: SBT 127 (3 ) 2 126 8.8 Trademarks 2,260 (199 ) (144 ) 1,917 13.8 Total intangible assets with finite lives 31,225 (2,197 ) (2,758 ) 26,270 Acquired in-process technology ― 6,650 — — 6,650 — Total intangible assets $ 37,875 $ (2,197 ) $ (2,758 ) $ 32,920
Summary of Estimated Future Amortization Expense of Intangible Assets	The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of March 31, 2017 (in thousands): Years Ending December 31, Cost of Product Sales and Marketing Total Remainder of 2017 $ 1,042 $ 692 $ 1,734 2018 1,390 923 2,313 2019 1,390 923 2,313 2020 1,390 923 2,313 2021 1,390 923 2,313 2022 1,390 923 2,313 Thereafter 5,606 7,365 12,971 Total future amortization expense $ 13,598 $ 12,672 $ 26,270

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Summary of Inventories	Inventory consisted of the following (in thousands): March 2017 December 2016 Finished goods $ 3,338 $ 4,199 Work in progress 1,745 159 Raw materials 965 1,103 Total inventory $ 6,048 $ 5,461

Accrued and Other Liabilities (

Accrued and Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Payables And Accruals [Abstract]
Components of Accrued and Other Liabilities	Accrued and other liabilities consisted of the following (in thousands): March 2017 December 2016 Clinical studies $ 1,456 $ 1,375 Tax, audit and compliance related fees 1,323 275 Accrued interest payable on debt 866 862 Professional fees 299 345 Debt financing fees — 600 Test sample processing fees 578 524 Customer overpayments and refund reserve 225 281 Software implementation costs 130 176 Deferred rent – current portion 383 374 Capital leases – current portion 43 68 Other accrued expenses 540 440 Total accrued and other liabilities $ 5,843 $ 5,320

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Commitments under Operating and Capital Leases	Future minimum lease commitments under these operating and capital leases at March 31, 2017, are as follows (in thousands): Years Ending December 31, Capital Leases Operating Leases Remainder of 2017 $ 39 $ 1,615 2018 24 2,060 2019 5 2,017 2020 — 1,994 2021 — 1 Total future minimum lease payments $ 68 $ 7,687

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Transfers And Servicing [Abstract]
Schedule of Debt	Debt consisted of the following (in thousands): March 31, December JGB Debt $ 20,922 $ — East West Bank Loan — 12,614 Danske Bank Credit Facility 7,434 7,376 FastPartner Subordinated Promissory Notes 1,724 1,692 Al Amoudi Subordinated Promissory Notes 1,187 1,164 SSP Primers Loan 1,119 — Current portion of long-term debt $ 32,386 $ 22,846 SSP Primers Loan $ — $ 1,098 Long-term debt, net of current portion $ — $ 1,098 As of March 31, 2017, future debt maturities were as follows (in thousands): Years Ending December 31, Amount Remainder of 2017 $ 4,076 2018 16,763 2019 11,250 2020 7,155 Total debt maturities 39,244 Less: debt discount and issuance costs (6,858 ) Total debt maturities, net of debt discount and issuance costs 32,386 Less: current portion of long-term debt (32,386 ) Long-term debt, net carrying value $ —

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2017
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Components of Warrants Outstanding	As of March 31, 2017, outstanding warrants to purchase Common Stock were: Original Term Exercise Price Number of Shares Underlying Warrants Original issue date: February 2008 10 years $ 35.10 22,792 August 2009 10 years $ 21.78 33,473 July 2010 9 years $ 21.78 6,694 December 2010 7 years $ 21.78 17,215 August 2012 7 years $ 21.78 167,182 January 2015 5 years $ 6.96 34,483 April 2016 (a) 7 years $ 4.00 1,775,580 April 2016 (b) 5 years $ 3.99 200,000 June 2016 (c) 7 years $ 4.00 1,002,507 March 2017 (d) 5 years $ 5.00 1,250,000 4,509,926 (a) Issued on April 14, 2016 in connection with the Private Placement to certain accredited investors. The exercise price was reset from $4.98 to $4.00 as a result of the Public Offering that closed on September 26, 2016. In accordance with the anti-dilution provisions, the exercise price of the warrants issued in connection with the Private Placement reset from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering, which closed on September 26, 2016. (b) Issued on April 14, 2016 in connection with the Private Placement to placement agents. (c) Issued on June 15, 2016 in connection with the Subsequent Financing. The exercise price was reset from $4.98 to $4.00 as a result of the Public Offering that closed on September 26, 2016. In accordance with the anti-dilution provisions, the exercise price of the warrants issued in connection with the Subsequent Financing reset from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering, which closed on September 26, 2016. (d) Issued on March 15, 2017 in connection with JGB Debt.

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Option, Unvested RSU Activity and Related Information	The following table summarizes option and unvested RSU activity under the plans and related information: Shares Available for Grant Stock Options Outstanding Weighted- Average Exercise Price Number of RSU Shares Weighted- Average Grant Date Fair Value Balance—December 31, 2016 365,074 1,792,286 $ 6.15 306,245 $ 5.69 Additional options authorized 357,075 — — Restricted stock grants (21,214 ) — — RSUs granted (182,500 ) — 182,500 2.30 RSUs forfeited 8,157 — (8,157 ) 5.46 RSUs vested — — (39,678 ) 5.75 Options granted (250,100 ) 250,100 2.33 — Options exercised — — — Options forfeited 26,668 (26,668 ) 8.63 — Options expired 26,140 (26,140 ) 6.75 — Balance—March 31, 2017 329,300 1,989,578 $ 5.62 440,910 $ 4.29
Summary of Options Outstanding and Exercisable Vested or Expected to Vest	Options outstanding that have vested or are expected to vest as of March 31, 2017 are as follows: Number of Shares Weighted Exercise Price Weighted Aggregate Intrinsic (In Vested 1,091,452 $ 6.01 6.54 $ 165 Expected to vest 789,964 5.17 8.85 — Total 1,881,416 $ 5.66 7.51 $ 165
Weighted-Average Assumptions Used to Estimate Fair Value of Share-Based Awards	The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Three Months Ended March 31, 2017 2016 Employee stock options Expected term (in years) 6.0 6.0 Expected volatility 53.07% – 53.36% 39.60% – 39.69% Risk-free interest rate 2.08% – 2.12% 1.54% – 1.65% Expected dividend yield — % — % Employee stock purchase plan Expected term (in years) 0.5 0.5 Expected volatility 62.27 % 64.21 % Risk-free interest rate 0.65 % 0.49 % Expected dividend yield — % — %
Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs	The following table summarizes stock-based compensation expense relating to employee and nonemployee stock options, RSUs and ESPP shares for the three months ended March 31, 2017 and 2016, included in the statements of operations as follows (in thousands): Three Months Ended March 31, 2017 2016 Cost of testing $ 55 $ 28 Research and development 64 113 Sales and marketing 38 28 General and administrative 234 277 Total $ 391 $ 446

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Operating Results of Reportable Segments	The following table summarizes the operating results of the Company’s reportable segments (in thousands): Three 2017 2016 Total segments Net revenues $ 11,584 $ 6,562 Operating loss (8,544 ) (6,569 ) Depreciation and amortization 934 261 CareDx Net revenues $ 7,917 $ 6,562 Operating loss (5,459 ) (6,569 ) Depreciation and amortization 262 261 Olerup Net revenues $ 3,667 $ — Operating loss (3,085 ) — Depreciation and amortization 672 — March 31, December Assets: CareDx $ 45,507 $ 41,169 Olerup 34,815 35,561 Total assets $ 80,322 $ 76,730
Reportable Revenues by Geographic Regions	Revenues by geographic regions are based upon the customers’ ship-to address or headquarters location. The following table summarizes reportable revenues by geographic regions (in thousands): Three 2017 2016 Revenues: North America $ 8,902 $ 6,562 Europe, Middle East and Africa 2,408 — Latin America 158 — Australia 116 — Total $ 11,584 $ 6,562
Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions	The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands): March 31, December Long-lived assets: United States $ 1,843 $ 2,052 Europe 829 879 Australia 96 — Total $ 2,768 $ 2,931

Organization and Description 37

Organization and Description of Business - Additional Information (Detail) $ in Thousands	Mar. 15, 2017USD ($)	Mar. 31, 2017USD ($)Segment	Apr. 18, 2017$ / d	Dec. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Schedule of Capitalization, Equity [Line Items]
Number of reportable segments | Segment		2
Accumulated deficit		$ 218,115		$ 212,553
Cash and cash equivalents		12,187		$ 17,258	$ 23,752	$ 29,888
Debt outstanding under debt and capital lease obligations		32,400
Proceeds from debt, net of issuance costs		24,002
Pay-off of term debt		11,200
JGB Debt [Member]
Schedule of Capitalization, Equity [Line Items]
Proceeds from debt, net of issuance costs	$ 24,000
Pay-off of term debt	11,200
Minimum cash requirement	$ 9,400	$ 9,400
JGB Debt [Member] | Subsequent Event [Member]
Schedule of Capitalization, Equity [Line Items]
Accruing liquidated damages payable amount per day | $ / d			7,000

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)Segment	Mar. 31, 2016USD ($)	Mar. 15, 2017USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash equivalents maturity, description	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
Impairment of Long-lived Assets	$ 0
Number of reportable segments | Segment	2
Goodwill impairment	$ 1,958,000	$ 0
Revenue recognition under milestone method	0	$ 0
Olerup [Member]
Summary Of Significant Accounting Policies [Line Items]
Goodwill impairment	$ 1,958,000
Laboratory, Computer, and Office Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	3 years
Furniture and Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	7 years
Capitalized Internal-use Software Costs [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	3 years
JGB Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Minimum cash requirement	$ 9,400,000		$ 9,400,000
Maximum [Member] | Olerup [Member]
Summary Of Significant Accounting Policies [Line Items]
Goodwill impairment	$ 2,000,000
Allenex [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company ownership percentage	100.00%

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Additional Information - Concentration of Credit Risk (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Services Revenue [Member] | Customer Concentration Risk [Member] | Minimum [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	10.00%
Services Revenue [Member] | Customer Concentration Risk [Member] | Medicare [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	28.00%	47.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Minimum [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%		10.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Medicare [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%		27.00%

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net loss attributable to CareDx, Inc. used to compute basic net loss per share	$ (5,562)	$ (9,752)
Net loss attributable to CareDx, Inc. used to compute diluted net loss per share	$ (5,562)	$ (9,752)
Denominator:
Weighted-average shares used to compute basic net loss per share attributable to CareDx, Inc.	21,343,782	11,969,714
Weighted-average shares used to compute diluted net loss per share attributable to CareDx, Inc.	21,343,782	11,969,714
Net loss per share attributable to CareDx, Inc.:
Basic	$ (0.26)	$ (0.81)
Diluted	$ (0.26)	$ (0.81)

Net Loss Per Share - Potentiall

Net Loss Per Share - Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders, Total	12,924,357	2,340,464
Shares of common stock subject to outstanding options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders, Total	1,881,416	1,860,420
Shares of common stock subject to outstanding common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders, Total	4,509,926	301,069
Shares of common stock subject to convertible notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders, Total	6,092,105	0
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders, Total	440,910	178,975

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	Sep. 26, 2016	Jun. 15, 2016	Apr. 14, 2016	Mar. 31, 2017	Dec. 31, 2016
Schedule of Net Income (Loss) Per Share [Line Items]
Preferred stock issued pursuant to Private Placement			4,630,145
Preferred stock issued pursuant to Subsequent Financing		4,630,145
Preferred stock, shares outstanding				0	0
Public Offering [Member]
Schedule of Net Income (Loss) Per Share [Line Items]
Common stock shares issued	2,250,000

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Assets
Money market funds	$ 11,723	$ 14,497
Liabilities
Contingent consideration	271	492
Common stock warrant liability	2,759	5,208
Derivative liability	1,510
Total liabilities	4,540	5,700
Fair Value Measured Using - (Level 1) [Member]
Assets
Money market funds	11,723	14,497
Liabilities
Contingent consideration	0	0
Common stock warrant liability	0	0
Derivative liability	0
Total liabilities	0	0
Fair Value Measured Using - (Level 2) [Member]
Assets
Money market funds	0	0
Liabilities
Contingent consideration	0	0
Common stock warrant liability	0	0
Derivative liability	0
Total liabilities	0	0
Fair Value Measured Using - (Level 3) [Member]
Assets
Money market funds	0	0
Liabilities
Contingent consideration	271	492
Common stock warrant liability	2,759	5,208
Derivative liability	1,510
Total liabilities	$ 4,540	$ 5,700

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Issuances, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Detail) - Fair Value Measured Using - (Level 3) [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	$ 5,700
Issuance of JGB debt and warrants	3,190
Change in estimated fair value	(4,350)
Ending Balance	4,540
Common Stock Warrant Liability [Member]
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	5,208
Issuance of JGB debt and warrants	900
Change in estimated fair value	(3,349)
Ending Balance	2,759
Contingent Consideration Liability [Member]
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	492
Issuance of JGB debt and warrants	0
Change in estimated fair value	(221)
Ending Balance	271
Derivative Liability [Member]
Significant Unobservable Inputs (Level 3) [Line Items]
Beginning Balance	0
Issuance of JGB debt and warrants	2,290
Change in estimated fair value	(780)
Ending Balance	$ 1,510

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2017USD ($)CommercialTestshares	Dec. 31, 2016USD ($)shares	Mar. 15, 2017shares	Jun. 15, 2016shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers between Level 1, Level 2 and Level 3 categories during the periods | $	$ 0	$ 0
Warrants outstanding				1,002,507
JGB Debt [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant to purchase stock, shares	1,250,000		1,250,000
Fair Value Measured Using - (Level 3) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Decrease in fair value of contingent consideration | $	$ 4,350,000
Warrants outstanding	2,978,087
Fair Value Measured Using - (Level 3) [Member] | Contingent Consideration Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Decrease in fair value of contingent consideration | $	$ 221,000
ImmuMetrix, Inc. [Member] | Contingent consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent obligation to issue common stock	227,845	227,845
Milestone description	The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of dd-cfDNA in organ transplant recipients in the United States by June 10, 2020.
Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTest	2,500
Probability of the achievement	85.00%	80.00%

Fair Value Measurements - Sum46

Fair Value Measurements - Summary of Common Stock Warrant Liability and Derivative Liability Assumptions (Detail) - $ / shares	Mar. 15, 2017	Mar. 31, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock Price		$ 1.40
Private Placement Common Stock Warrant Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock Price		1.40	$ 2.70
Exercise Price		$ 4	$ 4
Remaining term (in years)		6 years 15 days	6 years 3 months 15 days
Volatility		54.00%	51.40%
Risk-free interest rate		2.08%	2.14%
Placement Agent Common Stock Warrant Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock Price		$ 1.40	$ 2.70
Exercise Price		$ 3.99	$ 3.99
Remaining term (in years)		4 years 15 days	4 years 3 months 15 days
Volatility		60.30%	56.10%
Risk-free interest rate		1.72%	1.77%
JGB Common Stock Warrant Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock Price	$ 2.15	$ 1.40
Exercise Price	$ 5	$ 5
Remaining term (in years)	5 years 6 months	5 years 5 months 16 days
Volatility	54.00%	56.00%
Risk-free interest rate	2.06%	1.98%
Derivative Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock Price	$ 2.15	$ 1.40
Remaining term (in years)	2 years 11 months 15 days	2 years 10 months 28 days
Volatility	54.00%	56.00%
Risk-free interest rate	1.72%	1.61%

Business Combination - Addition

Business Combination - Additional Information (Detail)	Jul. 01, 2017USD ($)	Jan. 20, 2017USD ($)	Jan. 01, 2017	Apr. 14, 2016USD ($)shares	Mar. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Apr. 14, 2016SEKSEK / shares
Business Acquisition [Line Items]
Business acquisition deferred payment consideration					$ 1,018,000	$ 1,018,000
Noncontrolling interest					$ 227,000	$ 227,000		$ 279,000
Price per share of Allenex used to determine fair value of non controlling interest | $ / shares					$ 1.40	$ 1.40
Total revenue						$ 11,584,000	$ 6,562,000
Net loss						$ 5,562,000	9,752,000
Allenex [Member]
Business Acquisition [Line Items]
Percentage of share acquired				98.30%					98.30%
Total purchase price combination of cash and common stock				$ 34,100,000
Cash distribution to acquire business, gross				$ 26,900,000
Common stock, shares issue | shares				1,375,029
Common stock value				$ 7,200,000
Business acquisition deferred payment consideration				5,700,000					SEK 50,620,000
Escrow deposit				$ 8,000,000
Business acquisition deferred payment extended date						Jul. 1, 2017
Percentage of non controlling interest				1.70%					1.70%
Noncontrolling interest				$ 600,000	$ 227,000	$ 227,000		$ 279,000	SEK 5,100,000
Price per share of Allenex used to determine fair value of non controlling interest | SEK / shares									SEK 2.48
Allenex [Member] | Six-Month Bridge Loan [Member]
Business Acquisition [Line Items]
Business acquisition of debt financing cost						2,900,000	2,900,000
Allenex [Member] | Pro Forma [Member]
Business Acquisition [Line Items]
Business acquisition of related cost expenses						$ 2,300,000	$ 2,300,000
Allenex [Member] | Maximum [Member]
Business Acquisition [Line Items]
Business acquisition deferred payment date						Mar. 31, 2017
Allenex [Member] | Majority Shareholder [Member]
Business Acquisition [Line Items]
Percentage of accruing interest			10.00%
Conexio [Member]
Business Acquisition [Line Items]
Acquisition related quarterly payments, percentage on gross revenue		20.00%
Total revenue					100,000
Net loss					$ 123,000
Conexio [Member] | Scenario Forecast [Member]
Business Acquisition [Line Items]
Consideration to be paid for finished and unfinished goods acquired	$ 500,000
Conexio [Member] | Maximum [Member]
Business Acquisition [Line Items]
Acquisition related quarterly payments on gross revenue		$ 700,000
Obligations and liabilities assumed for product warranty claims		$ 35,000

Business Combination - Summary

Business Combination - Summary of Noncontrolling Interest (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Noncontrolling interest at December 31, 2016	$ 279
Loss attributable to noncontrolling interest	(47)	$ 0
Noncontrolling interest at March 31, 2017	227
Allenex [Member]
Business Acquisition [Line Items]
Noncontrolling interest at December 31, 2016	279
Foreign currency effect	(5)
Loss attributable to noncontrolling interest	(47)
Noncontrolling interest at March 31, 2017	$ 227

Business Combination - Summar49

Business Combination - Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed as of Acquisition Date (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Jan. 20, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 12,005		$ 13,839
Conexio [Member]
Business Acquisition [Line Items]
Inventory	1,040
Property, plant and equipment	97
Intangible assets	155	$ 155
Goodwill	85
Assumed liabilities	(82)
Total preliminary acquisition consideration	$ 1,295

Business Combination - Summar50

Business Combination - Summary of Identified Intangible Assets Acquired at Acquisition Date (Detail) - Conexio [Member] - USD ($) $ in Thousands	Jan. 20, 2017	Mar. 31, 2017
Business Acquisition [Line Items]
Estimated fair value of identified intangible assets	$ 155	$ 155
Completed Technology [Member]
Business Acquisition [Line Items]
Estimated fair value of identified intangible assets	$ 127
Estimated useful life of identified intangible asset	9 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated fair value of identified intangible assets	$ 28
Estimated useful life of identified intangible asset	9 years

Business Combination - Schedule

Business Combination - Schedule of Pro Forma Results of Operations (Detail) - Allenex and Conexio [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Revenue:
Testing revenue	$ 6,449
Product revenue	3,860
Other revenue	191
Total revenue	10,500
Net loss	$ (6,313)

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Summary of Goodwill by Reporting Unit (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Indefinite Lived Intangible Assets By Major Class [Line Items]
Goodwill, Beginning balance	$ 26,860
Accumulated impairment losses, Beginning balance	(13,021)
Goodwill net, Beginning balance	13,839
Goodwill acquired	85
Impairment losses	(1,958)	$ 0
Foreign currency translation adjustments	39
Goodwill, Ending balance	26,984
Accumulated impairment losses, Ending balance	(14,979)
Goodwill net, Ending balance	12,005
CareDx [Member]
Indefinite Lived Intangible Assets By Major Class [Line Items]
Goodwill, Beginning balance	12,005
Accumulated impairment losses, Beginning balance	0
Goodwill net, Beginning balance	12,005
Goodwill acquired	0
Impairment losses	0
Foreign currency translation adjustments	0
Goodwill, Ending balance	12,005
Accumulated impairment losses, Ending balance	0
Goodwill net, Ending balance	12,005
Olerup [Member]
Indefinite Lived Intangible Assets By Major Class [Line Items]
Goodwill, Beginning balance	14,855
Accumulated impairment losses, Beginning balance	(13,021)
Goodwill net, Beginning balance	1,834
Goodwill acquired	85
Impairment losses	(1,958)
Foreign currency translation adjustments	39
Goodwill, Ending balance	14,979
Accumulated impairment losses, Ending balance	(14,979)
Goodwill net, Ending balance	$ 0

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)ReportingUnit	Mar. 31, 2016USD ($)
Goodwill And Intangible Assets [Line Items]
Number of reporting units | ReportingUnit	2
Description of annual goodwill impairment test	On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The new standard simplifies how an entity is required to test goodwill for impairment and reduces the cost and complexity of evaluating goodwill for impairment. In the three months ended March 31, 2017, the Company determined that the decrease in its market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017.
Goodwill impairment	$ 1,958,000	$ 0
Amortization expense of intangible assets	600,000	$ 0
Acquired in-process research and development	6,700,000
Cost of Product [Member]
Goodwill And Intangible Assets [Line Items]
Amortization expense of intangible assets	400,000
Sales and marketing [Member]
Goodwill And Intangible Assets [Line Items]
Amortization expense of intangible assets	$ 200,000
Olerup [Member]
Goodwill And Intangible Assets [Line Items]
Description of goodwill impairment method for fair value determination	determined that the fair value of the Olerup reporting unit was $3.5 million, which was lower than its carrying value.
Fair value of reporting unit	$ 3,500,000
Goodwill impairment	$ 1,958,000
Reporting unit, discount rate	16.60%
Reporting unit, terminal growth rate	3.20%
Reporting unit, capitalization multiple	$ 7.48
Olerup [Member] | Maximum [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill impairment	2,000,000
CareDx [Member] | Maximum [Member]
Goodwill And Intangible Assets [Line Items]
Reporting unit, amount of fair value in excess of carrying value	$ 20,000,000

Goodwill and Intangible Asset54

Goodwill and Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Intangible assets with finite lives:
Gross Carrying Amount	$ 31,225
Accumulated Amortization	(2,197)
Foreign Currency Translation	(2,758)
Net Carrying Amount	26,270
Intangible assets with indefinite lives:
Gross Carrying Amount	6,700
Intangible Assets, Net (Excluding Goodwill)
Total intangible assets, Gross Carrying Amount	37,875
Total intangible assets, Accumulated Amortization	(2,197)
Total intangible assets, Foreign Currency Translation	(2,758)
Total intangible assets, net	32,920	$ 33,124
Acquired In Process Technology Cell Free D N A
Intangible assets with indefinite lives:
Gross Carrying Amount	6,650
Net Carrying Amount	6,650
Customer Relationships [Member]
Intangible assets with finite lives:
Gross Carrying Amount	12,678
Accumulated Amortization	(773)
Foreign Currency Translation	(1,150)
Net Carrying Amount	10,755
Customer Relationships [Member] | Allenex [Member]
Intangible assets with finite lives:
Gross Carrying Amount	12,650
Accumulated Amortization	(772)
Foreign Currency Translation	(1,151)
Net Carrying Amount	$ 10,727
Estimated useful life of identified intangible asset	13 years 9 months 18 days
Customer Relationships [Member] | Conexio [Member]
Intangible assets with finite lives:
Gross Carrying Amount	$ 28
Accumulated Amortization	(1)
Foreign Currency Translation	1
Net Carrying Amount	$ 28
Estimated useful life of identified intangible asset	8 years 9 months 18 days
Trademarks [Member]
Intangible assets with finite lives:
Gross Carrying Amount	$ 2,260
Accumulated Amortization	(199)
Foreign Currency Translation	(144)
Net Carrying Amount	$ 1,917
Estimated useful life of identified intangible asset	13 years 9 months 18 days
Developed Technology [Member] | SSP [Member]
Intangible assets with finite lives:
Gross Carrying Amount	$ 11,650
Accumulated Amortization	(1,076)
Foreign Currency Translation	(1,051)
Net Carrying Amount	$ 9,523
Estimated useful life of identified intangible asset	8 years 9 months 18 days
Acquired Technology - QTYPE
Intangible assets with finite lives:
Gross Carrying Amount	$ 4,510
Accumulated Amortization	(146)
Foreign Currency Translation	(415)
Net Carrying Amount	$ 3,949
Estimated useful life of identified intangible asset	13 years 9 months 18 days
Acquired Technology SBT [Member]
Intangible assets with finite lives:
Gross Carrying Amount	$ 127
Accumulated Amortization	(3)
Foreign Currency Translation	2
Net Carrying Amount	$ 126
Estimated useful life of identified intangible asset	8 years 9 months 18 days

Goodwill and Intangible Asset55

Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2017	$ 1,734
2,018	2,313
2,019	2,313
2,020	2,313
2,021	2,313
2,022	2,313
Thereafter	12,971
Net Carrying Amount	26,270
Cost of Product [Member]
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2017	1,042
2,018	1,390
2,019	1,390
2,020	1,390
2,021	1,390
2,022	1,390
Thereafter	5,606
Net Carrying Amount	13,598
Sales and marketing [Member]
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2017	692
2,018	923
2,019	923
2,020	923
2,021	923
2,022	923
Thereafter	7,365
Net Carrying Amount	$ 12,672

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 3,338	$ 4,199
Work in progress	1,745	159
Raw materials	965	1,103
Total inventory	$ 6,048	$ 5,461

Accrued and Other Liabilities -

Accrued and Other Liabilities - Components of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Clinical studies	$ 1,456	$ 1,375
Tax, audit and compliance related fees	1,323	275
Accrued interest payable on debt	866	862
Professional fees	299	345
Debt financing fees	0	600
Test sample processing fees	578	524
Customer overpayments and refund reserve	225	281
Software implementation costs	130	176
Deferred rent – current portion	383	374
Capital leases – current portion	43	68
Other accrued expenses	540	440
Total accrued and other liabilities	$ 5,843	$ 5,320

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 02, 2017USD ($)	Feb. 28, 2017USD ($)	Feb. 28, 2017SEK	Dec. 21, 2016USD ($)	Dec. 21, 2016SEK	Jul. 15, 2016USD ($)	Apr. 25, 2016USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Sep. 30, 2014USD ($)
Loss Contingencies [Line Items]
Rent expense under non-cancelable operating leases								$ 400,000	$ 300,000
Damages sought						$ 1,300,000
Fine by disciplinary committee				$ 100,000	SEK 1,000,000
Fine by disciplinary committee paid		$ 100,000	SEK 1,000,000
Oberland Complaint [Member]
Loss Contingencies [Line Items]
Damages sought							$ 1,400,000
Amount accrued for claim							$ 1,400,000
Settlement amount	$ (600,000)
Unpaid Royalties [Member]
Loss Contingencies [Line Items]
Settlement and mutual release agreement, counterparty name								Roche
Settlement and mutual release agreement, date								September 2,014
Past due royalties										$ 2,827,220
Maximum number of days from end of calendar quarter for royalty payment								45 days
Settlement and mutual release agreement, terms of agreement								In September 2014, the Company entered into a settlement and mutual release agreement with Roche whereby: (i)?for the period beginning July?1, 2011 through June?30, 2014, the Company agreed to pay the amount of $2,827,220 in settlement of past royalties due; (ii)?for the period beginning July?1, 2014 through September?30, 2014, the Company agreed to pay royalties based on the same combination services percentage used to determine the past royalties due; (iii)?for the period beginning October?1, 2014 through September?30, 2017, Roche and the Company agreed to a downward adjustment of the combination services percentage used to determine the portion of the AlloMap testing revenue that is royalty bearing under the terms of the license; (iv)?the Company agreed to report and pay quarterly royalties within 45 days of the end of each calendar quarter; (v)?Roche agreed that, subject to the Company?s timely payment of all applicable royalties through such date, no further royalties will be payable by the Company for periods after September?30, 2017.
Royalty expenses								$ 300,000	$ 200,000

Commitments and Contingencies59

Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Capital Leases (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
Capital Leases, Remainder of 2017	$ 39
Capital Leases, 2018	24
Capital Leases, 2019	5
Capital Leases, 2020	0
Capital Leases, 2021	0
Total minimum lease payments under capital leases	68
Operating Leases, Remainder of 2017	1,615
Operating Leases, 2018	2,060
Operating Leases, 2019	2,017
Operating Leases, 2020	1,994
Operating Leases, 2021	1
Total minimum lease payments under operating leases	$ 7,687

Collaboration and Licensing A60

Collaboration and Licensing Agreements - Additional Information (Detail)	1 Months Ended			3 Months Ended
	Jul. 31, 2013USD ($)	Jun. 30, 2013USD ($)	Jun. 30, 2013EUR (€)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2013EUR (€)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Description of agreement expire term				The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
Common stock value				$ 21,000		$ 21,000
Refundable upfront payments		$ 267,000	€ 250,000
Upfront cash payment		414,000	€ 387,500
Revenues and royalties recognized				0	$ 2,000
Royalty revenues				0	$ 96,000
Royalty revenues receivable balance				$ 0		$ 0
Diaxonhit [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value		$ 414,000					€ 387,500
Shares sold for consideration	$ 467,000

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Current portion of long-term debt	$ 32,386	$ 22,846
Long-term debt, net of current portion	0	1,098
JGB Debt [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	20,922	0
Danske Bank Credit Facility [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	7,434	7,376
East West Bank Loan [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	0	12,614
FastPartner Subordinated Promissory Notes [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	1,724	1,692
Al Amoudi Subordinated Promissory Notes [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	1,187	1,164
SSP Primers Loan [Member]
Debt Instrument [Line Items]
Current portion of long-term debt	1,119	0
Long-term debt, net of current portion	$ 0	$ 1,098

Debt - Additional Information (

Debt - Additional Information (Detail)

Mar. 15, 2017USD ($)$ / sharesshares

Mar. 07, 2016USD ($)

Dec. 29, 2015USD ($)

Jun. 18, 2015USD ($)

Feb. 25, 2015USD ($)

Feb. 25, 2015SEK

Jan. 30, 2015USD ($)$ / sharesshares

Jun. 28, 2013USD ($)

Jun. 28, 2013SEK

Jun. 25, 2013USD ($)

Mar. 31, 2017USD ($)$ / sharesshares

Mar. 31, 2017SEK

Mar. 31, 2017SEKshares

Dec. 31, 2016USD ($)

Aug. 04, 2016USD ($)

Aug. 04, 2016SEK

Mar. 07, 2016SEK

Dec. 29, 2015SEK

Jun. 18, 2015SEK

Feb. 25, 2015SEK

Jun. 28, 2013SEK

Jun. 25, 2013SEK

Debt Instrument [Line Items]

Proceeds from debt, net of issuance costs

$ 24,002,000

Pay-off of term debt

11,200,000

Aggregate principal amount

$ 20,000,000

Bank loan

0

$ 12,600,000

Debt extinguishment charges

$ 200,000

Loan agreement description

The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.

The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.

Estimated fair value of warrants

$ 90,000

Total accrued interest on debt

$ 800,000

$ 800,000

S S P Primers Aktieboulag | Allenex [Member]

Debt Instrument [Line Items]

Interest rate

3.00%

3.00%

Loan agreement initiation date

Feb. 25, 2015

Feb. 25, 2015

Term loan facility amount outstanding

$ 1,100,000

SEK 10,000,000

Principle amount of loan agreement

$ 1,600,000

SEK 14,000,000

Common Stock [Member]

Debt Instrument [Line Items]

Warrant to purchase stock, shares | shares

34,483

Warrant to purchase of stock, per share | $ / shares

$ 6.96

Warrants To Purchase Common Stock [Member]

Debt Instrument [Line Items]

Expected volatility rate

39.83%

Original Term

5 years

Risk-free interest rate

1.18%

Underlying common stock price | $ / shares

$ 7.06

Dividend yield

0.00%

Draw A [Member]

Debt Instrument [Line Items]

Non-refundable commitment fee

$ 160,000

Term Loan Facility | Allenex [Member]

Debt Instrument [Line Items]

Term loan facility amount outstanding

6,900,000

62,000,000

Term loan credit facility amount payable

$ 5,600,000

SEK 50,000,000

Term Loan Facility | Danske Bank A S | Allenex [Member]

Debt Instrument [Line Items]

Aggregate principal amount

$ 7,900,000

SEK 71,000,000

Loan agreement initiation date

Jun. 25, 2013

Term loan facility available for utilization advances

$ 600,000

5,000,000

Term loan facility integral multiples

$ 100,000

SEK 1,000,000

Interest rate basis spread

3.00%

Interest rate, description

0

0

Quarterly Payments from September 2017 through June 2018 [Member] | Allenex [Member]

Debt Instrument [Line Items]

Term loan credit facility amount payable

$ 300,000

SEK 3,000,000

Short Term Credit Facility | Danske Bank A S | Allenex [Member]

Debt Instrument [Line Items]

Aggregate principal amount

$ 900,000

$ 1,100,000

SEK 10,000,000

SEK 8,000,000

Loan agreement initiation date

Jun. 18, 2015

Short term credit facility

$ 500,000

SEK 4,400,000

Payable on February 25, 2016 [Member] | S S P Primers Aktieboulag | Allenex [Member]

Debt Instrument [Line Items]

Loan agreement, periodic payment

$ 400,000

SEK 4,000,000

Date of loan agreement payable.

Mar. 7, 2016

Mar. 7, 2016

Payable on February 27, 2017 [Member] | S S P Primers Aktieboulag | Allenex [Member]

Debt Instrument [Line Items]

Loan agreement, periodic payment

$ 1,100,000

SEK 10,000,000

Date of loan agreement payable.

Feb. 28, 2018

Feb. 28, 2018

JGB Debt [Member]

Debt Instrument [Line Items]

Aggregate principal amount

$ 27,800,000

Warrant to purchase stock, shares | shares

1,250,000

1,250,000

1,250,000

Proceeds from debt, net of issuance costs

$ 24,000,000

Pay-off of term debt

11,200,000

Minimum cash requirement

$ 9,400,000

$ 9,400,000

Debt instrument maturity date

Feb. 28, 2020

Interest rate

9.50%

Debentures convertible into common stock | shares

6,092,105

Conversion price per share | $ / shares

$ 4.56

Debt conversion description

Additionally, after September 1, 2017, upon the satisfaction of certain conditions, including the volume weighted average price of the Company’s common stock exceeding 250% of the Conversion Price for twenty consecutive trading days, the Company can require that the Debentures be converted into shares of the Company’s common stock, subject to certain limitations.

Debt, possible redemption amount after March 1, 2018

$ 937,500

Debt redemption description

Commencing on March 1, 2018, each of the holders of the Debentures shall have the right, at its option, to require the Company to redeem up to $937,500 of the outstanding principal amount of its Debenture per month. The Company will be required to promptly, but in any event no more than one trading day after the holder delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company’s election and subject to certain conditions, in shares of the Company’s common stock. If the Company elects to pay the redemption amount in shares of the Company’s common stock, then the shares will be delivered based on a price equal to the lowest of (a) 88% of the average of the three lowest volume weighted average prices of the Company’s common stock over the prior 20 trading days, (b) 88% of the prior trading day’s volume weighted average price, or (c) the Conversion Price.

Percentage of average three lowest volume weighted average prices of common stock if elected to pay in shares

88.00%

Percentage of prior trading day's volume weighted average price if elected to pay in shares

88.00%

Warrant to purchase of stock, per share | $ / shares

$ 5

JGB Debt [Member] | If Debentures are Prepaid on or Prior to March 1, 2018 [Member]

Debt Instrument [Line Items]

Prepayment premium percentage on principal amount

15.00%

15.00%

JGB Debt [Member] | If the Debentures are Prepaid After March 1, 2018 but Prior to March 1, 2019 [Member]

Debt Instrument [Line Items]

Prepayment premium percentage on principal amount

8.00%

8.00%

JGB Debt [Member] | If the Debentures are Prepaid on or After March 1, 2019 [Member]

Debt Instrument [Line Items]

Prepayment premium percentage on principal amount

5.00%

5.00%

JGB Debt [Member] | If Debenture is accelerated prior to March 1, 2018 [Member]

Debt Instrument [Line Items]

Percentage of debt principal and interest outstanding repayment

115.00%

JGB Debt [Member] | If Debenture is accelerated after March 1, 2018 but prior to March 1, 2019 [Member]

Debt Instrument [Line Items]

Percentage of debt principal and interest outstanding repayment

108.00%

JGB Debt [Member] | If Debenture is accelerated after March 1, 2019 [Member]

Debt Instrument [Line Items]

Percentage of debt principal and interest outstanding repayment

105.00%

Subordinated Promissory Note [Member] | FastPartner AB [Member] | Allenex [Member]

Debt Instrument [Line Items]

Aggregate principal amount

$ 400,000

$ 200,000

$ 1,100,000

SEK 4,000,000

SEK 2,000,000

SEK 9,400,000

Debt instrument maturity date

Dec. 31, 2016

Dec. 31, 2016

Jul. 1, 2017

Jul. 1, 2017

Interest rate

10.00%

10.00%

10.00%

10.00%

10.00%

10.00%

Issuance date

Mar. 7, 2016

Dec. 29, 2015

Jun. 28, 2013

Jun. 28, 2013

Principal payment

$ 100,000

SEK 1,000,000

Subordinated Promissory Note [Member] | Mohammed Al Amoudi [Member] | Allenex [Member]

Debt Instrument [Line Items]

Aggregate principal amount

$ 1,200,000

SEK 10,600,000

Debt instrument maturity date

Jun. 28, 2016

Jun. 28, 2016

Interest rate

10.00%

10.00%

Issuance date

Jun. 28, 2013

Jun. 28, 2013

Principal payment

$ 100,000

SEK 1,000,000

Debt instrument extended maturity date

Jul. 1, 2017

Jul. 1, 2017

Debt - Schedule of Future Debt

Debt - Schedule of Future Debt Maturities (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Equity Method Investments And Cost Method Investments [Abstract]
Remainder of 2017	$ 4,076
2,018	16,763
2,019	11,250
2,020	7,155
Total debt maturities	39,244
Less: debt discount and issuance costs	(6,858)
Total debt maturities, net of debt discount and issuance costs	32,386
Less: current portion of long-term debt	(32,386)	$ (22,846)
Long-term debt, net of current portion	$ 0	$ 1,098

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 26, 2016	Apr. 14, 2016	Mar. 31, 2017	Jun. 30, 2016	Sep. 25, 2016	Jun. 15, 2016	Jan. 30, 2015
Class Of Stock [Line Items]
Common stock purchase price		$ 3.99
Aggregate payment of Placement agent, escrow agents and legal fees		$ 1.8
Additional issued units				334,169
Warrants outstanding						1,002,507
M.M. Dillon & Co. Group [Member]
Class Of Stock [Line Items]
Placement fees		$ 0.2
Warrant to purchase stock, shares		100,000
Majority Shareholder [Member] | Allenex [Member]
Class Of Stock [Line Items]
Number of common stock purchased				1,002,507
Shares of common stock subject to outstanding common stock warrants [Member]
Class Of Stock [Line Items]
Proceeds from issuance of private placement offer		$ 3	$ 1.7
Common Stock [Member]
Class Of Stock [Line Items]
Proceeds from issuance of private placement offer		1.9	$ 1
Warrant to purchase stock, shares							34,483
Warrants outstanding			4,509,926
Exercise Price							$ 6.96
Series A Preferred Stock
Class Of Stock [Line Items]
Proceeds from issuance of private placement offer		$ 9.3	$ 5.3
Preferred shares convertible to common stock			1,670,845
Private Placement [Member]
Class Of Stock [Line Items]
Securities purchase agreement private placement units description			On April 14, 2016, the Company completed a Private Placement transaction for the offering of 591,860 units (“Units”) to certain accredited investors (the “Private Placement”). Each Unit was comprised of: (i) one share of common stock, (ii) five shares of Series A Preferred, and (iii) three warrants, each to purchase one share of common stock. The purchase price was $23.94 per Unit (the equivalent of $3.99 per share of common stock, assuming conversion of the Series A Preferred).
Common stock shares issued		591,860
Common stock offer price per share		$ 23.94
Proceeds from issuance of private placement offer		$ 14.2
Placement fees		$ 1.1
Warrants outstanding	1,775,580	1,975,580
Exercise Price	$ 4				$ 4.98
Public Offering [Member]
Class Of Stock [Line Items]
Common stock shares issued	2,250,000
Common stock offer price per share	$ 4
Gross proceeds from common stock shares issued at public offering	$ 9
Net proceeds from common stock shares issued at public offering	$ 7.8
Subsequent Financing [Member]
Class Of Stock [Line Items]
Warrants outstanding	1,002,507
Exercise Price	$ 4				4.98
Subsequent Financing [Member] | Common Stock [Member]
Class Of Stock [Line Items]
Exercise Price	$ 4				$ 4.98

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 15, 2017	Dec. 31, 2016	Sep. 26, 2016	Sep. 25, 2016	Jun. 15, 2016	Apr. 14, 2016	Jan. 30, 2015
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrants						$ 1,700
Warrants issued						1,002,507
Common stock warrant liability	$ 2,759		$ 5,208
Estimated fair value of warrant liability remeasurement charge	3,000
JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Common stock warrant liability	500	$ 900
Estimated fair value of warrant liability remeasurement charge	$ 400
Exercise Price	$ 5
Maximum [Member] | JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable date	Sep. 15, 2022
Minimum [Member] | JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable date	Sep. 16, 2017
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued	4,509,926
Exercise Price								$ 6.96
Common Stock [Member] | JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable date	Mar. 15, 2017
Common Stock [Member] | Maximum [Member] | JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued	1,250,000
Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrants							$ 3,300
Warrants issued				1,775,580			1,975,580
Exercise Price				$ 4	$ 4.98
Private Placement [Member] | Accredited Investors [Member]
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrants							$ 3,000
Warrants issued							1,775,580
Private Placement [Member] | Accredited Investors [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price				$ 4	4.98
Warrants exercisable date	Apr. 14, 2016
Private Placement [Member] | Placement Agents [Member]
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrants							$ 300
Warrants issued							200,000
Private Placement [Member] | Placement Agents [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable date	Apr. 14, 2016
Private Placement and Subsequent Financing [Member]
Class Of Warrant Or Right [Line Items]
Common stock warrant liability	$ 2,300		$ 5,200				$ 5,000
Subsequent Financing [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued				1,002,507
Exercise Price				$ 4	4.98
Subsequent Financing [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price				$ 4	$ 4.98
Warrants exercisable date	Jun. 15, 2016

Warrants - Outstanding Warrants

Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail) - $ / shares		3 Months Ended
		Mar. 31, 2017	Sep. 26, 2016	Sep. 25, 2016	Jun. 15, 2016	Apr. 14, 2016	Jan. 30, 2015
Class Of Warrant Or Right [Line Items]
Number of Shares Underlying Warrants					1,002,507
Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price			$ 4	$ 4.98
Number of Shares Underlying Warrants			1,775,580			1,975,580
Private Placement [Member] | Accredited Investors [Member]
Class Of Warrant Or Right [Line Items]
Number of Shares Underlying Warrants						1,775,580
Private Placement [Member] | Placement Agents [Member]
Class Of Warrant Or Right [Line Items]
Number of Shares Underlying Warrants						200,000
Subsequent Financing [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price			$ 4	4.98
Number of Shares Underlying Warrants			1,002,507
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price							$ 6.96
Number of Shares Underlying Warrants		4,509,926
Common Stock [Member] | Class Of Warrant Or Right Issued on February 2008 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date		2008-02
Original Term		10 years
Exercise Price		$ 35.10
Number of Shares Underlying Warrants		22,792
Common Stock [Member] | Class Of Warrant Or Right Issued on August 2009 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date		2009-08
Original Term		10 years
Exercise Price		$ 21.78
Number of Shares Underlying Warrants		33,473
Common Stock [Member] | Class Of Warrant Or Right Issued on July 2010 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date		2010-07
Original Term		9 years
Exercise Price		$ 21.78
Number of Shares Underlying Warrants		6,694
Common Stock [Member] | Class Of Warrant Or Right Issued on December 2010 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date		2010-12
Original Term		7 years
Exercise Price		$ 21.78
Number of Shares Underlying Warrants		17,215
Common Stock [Member] | Class Of Warrant Or Right Issued on August 2012 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date		2012-08
Original Term		7 years
Exercise Price		$ 21.78
Number of Shares Underlying Warrants		167,182
Common Stock [Member] | Class Of Warrant Or Right Issued on January 2015 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date		2015-01
Original Term		5 years
Exercise Price		$ 6.96
Number of Shares Underlying Warrants		34,483
Common Stock [Member] | Class Of Warrant Or Right Issued on March 2017 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date	[1]	2017-03
Original Term	[1]	5 years
Exercise Price	[1]	$ 5
Number of Shares Underlying Warrants	[1]	1,250,000
Common Stock [Member] | Private Placement [Member] | Accredited Investors [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price			$ 4	4.98
Common Stock [Member] | Private Placement [Member] | Accredited Investors [Member] | Class Of Warrant Or Right Issued on April 2016 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date	[2]	2016-04
Original Term	[2]	7 years
Exercise Price	[2]	$ 4
Number of Shares Underlying Warrants	[2]	1,775,580
Common Stock [Member] | Private Placement [Member] | Placement Agents [Member] | Class Of Warrant Or Right Issued on April 2016 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date	[3]	2016-04
Original Term	[3]	5 years
Exercise Price	[3]	$ 3.99
Number of Shares Underlying Warrants	[3]	200,000
Common Stock [Member] | Subsequent Financing [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price			$ 4	$ 4.98
Common Stock [Member] | Subsequent Financing [Member] | Class Of Warrant Or Right Issued on June 2016 [Member]
Class Of Warrant Or Right [Line Items]
Issue Date	[4]	2016-06
Original Term	[4]	7 years
Exercise Price	[4]	$ 4
Number of Shares Underlying Warrants	[4]	1,002,507
[1]	Issued on March 15, 2017 in connection with JGB Debt.
[2]	Issued on April 14, 2016 in connection with the Private Placement to certain accredited investors. The exercise price was reset from $4.98 to $4.00 as a result of the Public Offering that closed on September 26, 2016. In accordance with the anti-dilution provisions, the exercise price of the warrants issued in connection with the Private Placement reset from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering, which closed on September 26, 2016.
[3]	Issued on April 14, 2016 in connection with the Private Placement to placement agents.
[4]	Issued on June 15, 2016 in connection with the Subsequent Financing. The exercise price was reset from $4.98 to $4.00 as a result of the Public Offering that closed on September 26, 2016. In accordance with the anti-dilution provisions, the exercise price of the warrants issued in connection with the Subsequent Financing reset from $4.98 per share to $4.00 per share, which was the price paid by investors in the Public Offering, which closed on September 26, 2016

Warrants - Outstanding Warran67

Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Parenthetical) (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2017	Sep. 26, 2016	Sep. 25, 2016	Jan. 30, 2015
JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price	$ 5
Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price		$ 4	$ 4.98
Subsequent Financing [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price		4	4.98
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Exercise Price				$ 6.96
Common Stock [Member] | JGB Debt [Member]
Class Of Warrant Or Right [Line Items]
Warrants, issued date	Mar. 15, 2017
Common Stock [Member] | Private Placement [Member] | Accredited Investors [Member]
Class Of Warrant Or Right [Line Items]
Warrants, issued date	Apr. 14, 2016
Exercise Price		4	4.98
Common Stock [Member] | Private Placement [Member] | Placement Agents [Member]
Class Of Warrant Or Right [Line Items]
Warrants, issued date	Apr. 14, 2016
Common Stock [Member] | Subsequent Financing [Member]
Class Of Warrant Or Right [Line Items]
Warrants, issued date	Jun. 15, 2016
Exercise Price		$ 4	$ 4.98

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Information (Detail) - USD ($)	Jan. 02, 2014	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Apr. 21, 2016	Jan. 01, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of options exercised		$ 0
Total unrecognized compensation costs related to stock options and RSUs		$ 1,800,000
Stock options and RSUs expected weighted average period		2 years 3 months 26 days
Price per share of Allenex used to determine fair value of non controlling interest		$ 1.40
Weighted average fair value of options to purchase common stock granted		$ 1.20	$ 2.07
Total fair value of options vested during period		$ 400,000
Share-based compensation expense, tax benefit recognized		0
Share-based compensation costs, capitalized		0
Share based compensation, Total expensed		391,000	$ 446,000
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, Total expensed		$ 234,000	277,000
Non Employee Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued		126,155
Fair value of shares issued		$ 620,000
Non Employee Director [Member] | General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, Total expensed		43,000	$ 79,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of RSUs		617,000
Total unrecognized compensation costs related to stock options and RSUs		$ 21,000,000
Stock options and RSUs expected weighted average period		3 years 29 days
RSUs vest annual equal increments (in years)		4 years
RSUs granted period		2015-03
Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs granted period		2016-06
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance of common stock		838,695				357,075
Outstanding shares of common stock, in percentage	4.00%
2014 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares may be added to the plan hereunder		865,252
2016 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of common stock shares that might be granted					155,500
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate proceeds from the issuance of shares				$ 44,000
Shares issued under ESPP				19,027
Applicable exercise date an offering period shall be equal to percentage of the lesser of fair market value of common stock		85.00%

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Option, Unvested RSU Activity and Related Information (Detail)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning Balance	365,074
Shares Available for Grant, Additional options authorized	357,075
Shares Available for Grant, RSUs forfeited	8,157
Shares Available for Grant, RSUs vested	0
Shares Available for Grant, Options granted	(250,100)
Shares Available for Grant, Options exercised	0
Shares Available for Grant, Options forfeited	26,668
Shares Available for Grant, Options expired	26,140
Shares Available for Grant, Ending Balance	329,300
Number of Shares, Beginning Balance	1,792,286
Number of Shares, Additional options authorized	0
Number of Shares, Options granted	250,100
Number of Shares, Options forfeited	(26,668)
Number of Shares, Options expired	(26,140)
Number of Shares, Ending Balance	1,989,578
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 6.15
Weighted-Average Exercise Price, Additional options authorized | $ / shares	0
Weighted-Average Exercise Price, Options granted | $ / shares	2.33
Weighted-Average Exercise Price, Options exercised | $ / shares	0
Weighted-Average Exercise Price, Options forfeited | $ / shares	8.63
Weighted-Average Exercise Price, Options expired | $ / shares	6.75
Weighted-Average Exercise Price, Ending Balance | $ / shares	$ 5.62
Number of RSU Shares, forfeited	(8,157)
Number of RSU Shares, vested	0
Restricted Stock Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant	(21,214)
Shares Available for Grant	21,214
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant	(182,500)
Shares Available for Grant, RSUs forfeited	8,157
Shares Available for Grant, RSUs vested	39,678
Number of RSU Shares, Beginning Balance	306,245
Shares Available for Grant	182,500
Number of RSU Shares, forfeited	(8,157)
Number of RSU Shares, vested	(39,678)
Number of RSU Shares, Ending Balance	440,910
Weighted Average Grant- Date Fair Value, Unvested beginning balance | $ / shares	$ 5.69
Weighted- Average Grant Date Fair Value, RSUs granted | $ / shares	2.30
Weighted- Average Grant Date Fair Value, RSUs forfeited | $ / shares	5.46
Weighted- Average Grant Date Fair Value, RSUs vested | $ / shares	5.75
Weighted Average Grant- Date Fair Value, Unvested ending balance | $ / shares	$ 4.29

Stock Incentive Plans - Summa70

Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Issued, Vested | shares	1,091,452
Number of Shares Issued, Expected to vest | shares	789,964
Number of Shares Issued, Total | shares	1,881,416
Weighted-average Exercise Price, Vested | $ / shares	$ 6.01
Weighted-average Exercise Price, Expected to vest | $ / shares	5.17
Weighted-average Exercise Price, Total | $ / shares	$ 5.66
Weighted-average Remaining Contractual Life (Years), Vested	6 years 6 months 15 days
Weighted-average Remaining Contractual Life (Years), Expected to vest	8 years 10 months 6 days
Weighted-average Remaining Contractual Life (Years), Total	7 years 6 months 4 days
Aggregate Intrinsic Value, Vested | $	$ 165
Aggregate Intrinsic Value, Total | $	$ 165

Stock Incentive Plans - Weighte

Stock Incentive Plans - Weighted-Average Assumptions Used to Estimated Fair Value of Share-Based Awards (Detail)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 months	6 months
Expected volatility	62.27%	64.21%
Risk-free interest rate	0.65%	0.49%
Expected dividend yield	0.00%	0.00%
Shares of common stock subject to outstanding options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	6 years
Risk-free interest rate, minimum	2.08%	1.54%
Risk-free interest rate, maximum	2.12%	1.65%
Expected dividend yield	0.00%	0.00%
Minimum [Member] | Shares of common stock subject to outstanding options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	53.07%	39.60%
Maximum [Member] | Shares of common stock subject to outstanding options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	53.36%	39.69%

Stock Incentive Plans - Summa72

Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share based compensation, Total expensed	$ 391	$ 446
Cost of testing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share based compensation, Total expensed	55	28
Research and Development Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share based compensation, Total expensed	64	113
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share based compensation, Total expensed	38	28
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share based compensation, Total expensed	$ 234	$ 277

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Benefit for income taxes	$ (283)	$ 0

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)Segment
Segment Reporting [Abstract]
Number of reportable segments | Segment	2
Intersegment sales | $	$ 0

Segment Reporting - Operating R

Segment Reporting - Operating Results of Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net revenues	$ 11,584	$ 6,562
Operating loss	(8,544)	(6,569)
Depreciation and amortization	934	261
Total assets	80,322		$ 76,730
CareDx [Member]
Segment Reporting Information [Line Items]
Net revenues	7,917	6,562
Operating loss	(5,459)	(6,569)
Depreciation and amortization	262	261
Total assets	45,507		41,169
Olerup [Member]
Segment Reporting Information [Line Items]
Net revenues	3,667	0
Operating loss	(3,085)	0
Depreciation and amortization	672	$ 0
Total assets	$ 34,815		$ 35,561

Segment Reporting - Reportable

Segment Reporting - Reportable Revenues by Geographic Regions (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Net revenues	$ 11,584	$ 6,562
North America [Member]
Segment Reporting Information [Line Items]
Net revenues	8,902	6,562
Europe, Middle East and Africa [Member]
Segment Reporting Information [Line Items]
Net revenues	2,408	0
Latin America [Member]
Segment Reporting Information [Line Items]
Net revenues	158	0
Australia [Member]
Segment Reporting Information [Line Items]
Net revenues	$ 116	$ 0

Segment Reporting - Long-Lived

Segment Reporting - Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Long-lived assets	$ 2,768	$ 2,931
United States [Member]
Segment Reporting Information [Line Items]
Long-lived assets	1,843	2,052
Europe [Member]
Segment Reporting Information [Line Items]
Long-lived assets	829	879
Australia [Member]
Segment Reporting Information [Line Items]
Long-lived assets	$ 96	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member]	May 22, 2017shares	Apr. 19, 2017shares	Apr. 26, 2017shares	Apr. 18, 2017$ / d
Subsequent Event [Line Items]
Common stock shares registered for resale to be issued upon conversion or redemption of debentures or the exercise of warrants			8,250,000
JGB Debt [Member]
Subsequent Event [Line Items]
Accruing liquidated damages payable amount per day | $ / d				7,000
Common Stock [Member] | Maximum [Member]
Subsequent Event [Line Items]
Restriction on sale of common stock	8,534,261	8,534,261